[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 140
1. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM: Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood; 2008 Apr 1;111(7):3377-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma.
  • Young adult Hodgkin lymphoma (YAHL) is associated clinically with altered immunity, including a systemic defect in cell-mediated responses.
  • We identified twin pairs in whom at least one member had YAHL and measured interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-gamma) levels in PHA-stimulated peripheral blood mononuclear cell supernatant in 90 case-twins, 84 of their disease-free twins (unaffected cotwins), and 90 matched controls.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Oct 15;175(8):5457-62 [16210653.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Genes Immun. 2000 Dec;1(8):515-20 [11197695.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):218-21 [11175794.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] Twin Res. 2001 Aug;4(4):242-50 [11665304.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):69-75 [11905816.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):545-52 [12845650.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Biometrics. 1982 Sep;38(3):715-24 [7171697.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):673-82 [2251514.001]
  • [Cites] Nature. 1996 Jul 11;382(6587):174-7 [8700209.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):1658-65 [9257825.001]
  • [Cites] Genes Immun. 2004 Dec;5(8):675-7 [15483662.001]
  • [Cites] Hum Immunol. 2004 Dec;65(12):1432-6 [15603869.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):740-8 [15643599.001]
  • [Cites] Genes Immun. 2005 Mar;6(2):167-70 [15674372.001]
  • [Cites] Intensive Care Med. 2005 Mar;31(3):401-7 [15719148.001]
  • [Cites] Cytokine. 2005 May 21;30(4):188-94 [15863393.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):125-35 [16510856.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2062-3 [16990781.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • (PMID = 18077789.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2275007
  •  go-up   go-down


2. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DM, Nathwani BN, Weiss LM, Mack TM: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood; 2009 Nov 5;114(19):4014-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.
  • The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2313-22 [12788995.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] J Natl Cancer Inst. 1973 Jun;50(6):1429-35 [4717560.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Br Med J. 1978 Feb 11;1(6109):327-9 [623979.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4507-11 [498082.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] J Clin Epidemiol. 1989;42(12):1207-13 [2585011.001]
  • [Cites] J Clin Gastroenterol. 1990 Apr;12(2):127-9 [2157745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1045-7 [9569037.001]
  • [Cites] Clin Exp Allergy. 1999 Mar;29(3):342-6 [10202341.001]
  • [Cites] Lancet. 1999 Sep;354 Suppl 2:SII12-5 [10507253.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):617-22 [15622446.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):89-93 [16309494.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):251-6 [16533224.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Neurology. 2007 Jul 24;69(4):381-8 [17646631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1561-6 [17684129.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3377-82 [18077789.001]
  • [Cites] BMC Immunol. 2008;9:65 [18990206.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1590-6 [11069568.001]
  • (PMID = 19738032.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836-01A2; United States / NCI NIH HHS / CA / R03CA110836-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2774542
  •  go-up   go-down


3. Chiu A, Frizzera G, Mathew S, Hyjek EM, Chadburn A, Tam W, Knowles DM, Orazi A: Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. Mod Pathol; 2009 Nov;22(11):1507-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma.
  • Among the diffuse lymphomas of B-cell origin, we have encountered one variant displaying blastoid features that morphologically mimic lymphoblastic lymphoma, the blastoid variant of mantle cell lymphoma, and the so-called blastoid transformation of follicular lymphoma.
  • To better characterize this entity, we studied eight cases morphologically, immunohistochemically, and by fluorescence in situ hybridization (FISH) for cytogenetic abnormalities commonly associated with follicular lymphoma and B-cell lymphomas exhibiting high-grade histological features.
  • All eight cases were presented as de novo neoplasms, and displayed an entirely diffuse (five cases) or only minimal follicular (three cases) growth pattern.
  • The neoplastic lymphoid cells were of medium size with round nuclei, fine chromatin, inconspicuous nucleoli, and high mitotic rate; they expressed CD10, BCL6, and BCL2-a phenotype consistent with follicle center cell origin.
  • Their lack of TdT and CYCLIN D1 distinguished them from lymphoblastic lymphoma and the blastoid mantle cell lymphoma, respectively.
  • The neoplastic lymphoid cells consistently expressed CD43 (seven of eight cases) and occasionally other T-cell-associated antigens, including CD5, CD7, CD8, and CD57.
  • The combination of a B-cell CD10+ BCL6+ BCL2+ phenotype in the presence of structural abnormalities of BCL6 is consistent with a follicular center cell derivation for our cases.
  • The lack of t(14;18) seen in our cases, although rare in most cases of follicular lymphoma, has been nevertheless reported in cases of follicular lymphoma with a predominantly diffuse growth pattern.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. B-Lymphocytes / metabolism. Cytogenetic Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Interferon Regulatory Factors / genetics. Interferon Regulatory Factors / metabolism. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633642.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / interferon regulatory factor-4
  •  go-up   go-down


Advertisement
4. Dulai MS, Park CY, Howell WD, Smyth LT, Desai M, Carter DM, Vogel H: CNS T-cell lymphoma: an under-recognized entity? Acta Neuropathol; 2008 Mar;115(3):345-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS T-cell lymphoma: an under-recognized entity?
  • The incidence of CNS lymphoma has increased significantly in the past 30 years, primarily in the elderly and immunocompromised.
  • While T-cell lymphomas comprise 15-20% of systemic lymphomas, they comprise less than 4% of primary CNS lymphomas, suggesting that they may be under-recognized compared to their systemic counterparts.
  • To investigate this, we studied brain biopsies from three patients who were diagnosed with T-cell lymphoma confined to the brain.
  • We compared these to biopsies from three patients who had reactive lymphoid infiltrates and who had clinical signs/symptoms and radiographic findings that were indistinguishable from the lymphoma group.
  • Biopsies from both the lymphoma group and reactive group showed considerable cytomorphologic heterogeneity.
  • Although one lymphoma case contained large atypical cells, the other two contained small, mature lymphocytes within a heterogeneous infiltrate of neoplastic and reactive inflammatory cells.
  • Surface marker aberrancies were present in two lymphoma cases, but this alone could not reliably diagnose T-cell lymphoma.
  • The proliferation index was not useful for differentiating lymphoma from reactive infiltrates.
  • In five of the six cases the diagnosis was most influenced by clonality studies for T-cell receptor-gamma gene rearrangements.
  • We conclude that because of the high degree of overlap in cytomorphologic and immunophenotypic features between T-cell lymphoma and reactive infiltrates, T-cell lymphoma may not be recognized unless studies for T-cell receptor gene rearrangements are performed for CNS lesions composed of a polymorphous but predominantly T-cell infiltrate.
  • [MeSH-major] Brain Diseases / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunohistochemistry. In Situ Hybridization. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196250.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Balasubramaniam R, Goradia A, Turner LN, Stoopler ET, Alawi F, Frank DM, Greenberg MS: Burkitt lymphoma of the oral cavity: an atypical presentation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Feb;107(2):240-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the oral cavity: an atypical presentation.
  • Burkitt lymphoma (BL) is an aggressive form of non-Hodgkin B-cell lymphoma with 3 variants: endemic, sporadic, and immunodeficiency-associated types.
  • An incisional biopsy revealed a diffuse proliferation of intermediate- to large-sized lymphocytes with multiple small peripheral nucleoli, scant cytoplasm, and nuclear pleomorphism.
  • [MeSH-major] Burkitt Lymphoma / pathology. Gingival Neoplasms / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Infusions, Intralesional. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138642.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


6. Dalloul M, Sherer DM, Gorelick C, Serur E, Zinn H, Sanmugarajah J, Zigalo A, Abulafia O: Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma. Ultrasound Obstet Gynecol; 2007 Feb;29(2):236-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma.
  • Ovarian malignancies include epithelial, stromal and germ-cell tumors.
  • Primary malignancies that may exhibit metastases to the ovaries include gastrointestinal, breast and soft tissue tumors such as lymphoma.
  • Subsequent computerized tomography (CT) imaging depicted a large retroperitoneal tumor, CT-guided biopsy of which revealed diffuse large B cell lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Hypertrophy / etiology. Hypertrophy / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 17252529.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J: Array-based DNA methylation profiling in follicular lymphoma. Leukemia; 2009 Oct;23(10):1858-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-based DNA methylation profiling in follicular lymphoma.
  • Quantitative methylation profiling was performed using the Illumina GoldenGate Assay in untreated follicular lymphoma (FL) (164), paired pre- and post-transformation FL (20), benign haematopoietic (24) samples and purified B and T cells from two FL cases.
  • [MeSH-major] DNA Methylation. Gene Expression Profiling. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. CpG Islands. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3060-71 [15126342.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):919-25 [3284977.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1459-65 [15902285.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):430-9 [16191512.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):738-40 [16804535.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1075-83 [16899657.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1855-62 [16900213.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1658-60 [17041636.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1443-4 [17047192.001]
  • [Cites] Mol Cancer. 2006;5:44 [17026765.001]
  • [Cites] Curr Pharm Biotechnol. 2006 Oct;7(5):315-21 [17076647.001]
  • [Cites] Leukemia. 2007 Jan;21(1):18-29 [17039231.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52 [17023173.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):391-403 [17272646.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1040-3 [17457052.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1514-20 [17495976.001]
  • [Cites] Nat Protoc. 2007;2(9):2265-75 [17853883.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8511-8 [17875690.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1083-94 [17825402.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1304-15 [17999367.001]
  • [Cites] PLoS One. 2007;2(12):e1289 [18074014.001]
  • [Cites] Genome Res. 2008 May;18(5):780-90 [18316654.001]
  • [Cites] Leukemia. 2008 May;22(5):1035-43 [18288132.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10280-9 [19074896.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):758-64 [19155300.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2298-301 [19141865.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Haematologica. 2004 Feb;89(2):154-64 [15003890.001]
  • (PMID = 19587707.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United Kingdom / Cancer Research UK / / A9424; United Kingdom / Cancer Research UK / / A8314; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / 5 U01 CA114778; United Kingdom / Cancer Research UK / / MONG1E9R
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2762475; NLM/ UKMS4607
  •  go-up   go-down


8. Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW: Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol; 2010;3(8):763-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective central nervous system tropism of primary central nervous system lymphoma.
  • Primary Central nervous system lymphoma (PCNSL) is most frequently a diffuse large B cell lymphoma (DLBCL), which is confined to the Central nervous system (CNS).
  • We performed an experiment in which lymphoma cells from a PCNSL patient were implanted subcutaneously in an athymic mouse.
  • The lymphoma cells were shown to home to the CNS with histologic evaluations of the brain showing multiple large B cells in blood vessels consistent with intravascular large B cell lymphoma (IVL).
  • We did not find any evidence of lymphoma at the site of implantation or other locations.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Animals. Biomarkers, Tumor / metabolism. Brain / blood supply. Brain / pathology. Cell Movement. Fatal Outcome. Female. Humans. Lymphocytes / pathology. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Osteopontin / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1058-67 [12690046.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):231-6 [15028023.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1267-85 [17113462.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):73-80 [19080745.001]
  • [Cites] Blood. 2009 Jan 1;113(1):266-7; author reply 267-8 [19122120.001]
  • (PMID = 21151389.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2993226
  • [Keywords] NOTNLM ; Lymphoma / central nervous system / tropism
  •  go-up   go-down


9. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM: Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma; 2008 Oct;49(10):1893-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
  • The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of FL patients.
  • Studies reporting outcomes of transformed FL patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are scant.
  • Eight FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent HSCT at our institution.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Feasibility Studies. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Salvage Therapy. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous


10. Bi R, Lin DM, Han YL, Lu J, Xue LY, Zheng S, Wang MR, Lü N: [Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):733-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma].
  • METHODS: A total of 74 fresh tissue samples clinically suspicious of lymphoma were investigated by FISH using three probes including IgH/bcl-2, IgH/CCND1 and API2/MALT1, corresponding the translocation t(14;18), t(11;14) and t(11;18) respectively.
  • RESULTS: Histological evaluation eventually confirmed that there were 62 cases of lymphoma and 12 cases of reactive lymphoid processes.
  • The translocations were detected in 7 cases in 62 cases of lymphoma: 3 demonstrated t(14;18) including 2 cases of follicular lymphomas and 1 nodular sclerosing Hodgkin lymphoma.
  • Four cases had t(11;14) including mantle cell lymphoma (2 cases), follicular lymphoma (1 case) and small cell lymphoma (1 case).
  • CONCLUSION: Interphase FISH offers useful ancillary technology that plays an important role in differential diagnosis and classification of lymphoma.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Lymphoma / diagnosis. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Diagnosis, Differential. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079011.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Wohltmann WE, MacAlpine DM, Hodson DS: Palmoplantar keratoderma as the initial sign in a peripheral T-cell lymphoma. Dermatol Online J; 2010;16(5):3
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmoplantar keratoderma as the initial sign in a peripheral T-cell lymphoma.
  • A 27-year-old male with an acquired severe, diffuse palmoplantar keratoderma as the initial sign of peripheral T-cell lymphoma is reported.
  • [MeSH-major] Keratoderma, Palmoplantar, Diffuse / complications. Lymphoma, T-Cell, Peripheral / complications. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Skin / pathology

  • Genetic Alliance. consumer health - Palmoplantar Keratoderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492820.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol; 2005 Aug 1;23(22):5044-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
  • PURPOSE: To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each.
  • Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]).
  • Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955901.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Xue LY, Lü N, Li AD, Zou SM, Lin DM, He ZG, Xie YQ, Liu XY: [A clinicopathological analysis of gastric lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):332-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathological analysis of gastric lymphoma].
  • OBJECTIVE: To discuss the clinicopathological features and prognostic factors of gastric lymphoma.
  • METHODS: 83 gastric lymphoma cases were analyzed retrospectively in accordance to the criteria of the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues.
  • According to the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues, 57 cases were extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type (MALT lymphoma), 23 were diffuse large B cell lymphoma accompanying MALT lymphoma, 2 were diffuse large B cell lymphoma and 1 was follicular lymphoma.
  • The 5-year and 10-year survival rates of MALT lymphoma were 77.4% and 72.3%, the 5-year and 10-year survival rates of diffuse large B cell lymphoma accompanying MALT lymphoma were 81.8% and 68.2%, the 5-year survival rate of diffuse large B cell lymphoma was 50.0%.
  • CONCLUSIONS: There are no specific symptoms in gastric lymphoma patients.
  • Extranodal marginal zone lymphoma of MALT-type is the main histopathological type of gastric lymphoma, often accompanied by multiple mucosa involvement and also often accompanied by a history of chronic gastric disease.
  • [MeSH-major] Gastrectomy. Lymphoma / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185499.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Russell NC, Hoelscher DM, Janszen L, Rodriguez MA: Dietary and weight changes after treatments for lymphoma. Nutr Cancer; 2007;57(2):168-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary and weight changes after treatments for lymphoma.
  • To estimate the current prevalence of overweight and any associations with self-reported changes in dietary patterns, we surveyed 141 patients who had completed treatments for lymphoma at The M. D.
  • [MeSH-major] Body Mass Index. Diet / standards. Lymphoma / therapy. Obesity / epidemiology. Perception
  • [MeSH-minor] Adult. Body Weight / drug effects. Body Weight / physiology. Cross-Sectional Studies. Edible Grain. Female. Fruit. Humans. Male. Middle Aged. Retrospective Studies. Surveys and Questionnaires. Vegetables

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571950.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ren LQ, Xue LY, Bi R, Liang JM, Lin DM, Ma J, Lü N: [Application of flow cytometric immunophenotypic analysis in the diagnosis of malignant lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):671-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of flow cytometric immunophenotypic analysis in the diagnosis of malignant lymphoma].
  • OBJECTIVE: To explore the value of flow cytometric immunophenotyping (FCI) in the diagnosis and differentiated diagnosis of lymphoma and explain the immunophenotypic features and differences of malignant lymphoma.
  • METHODS: Seventy four fresh samples of suspicious lymphoma were collected from Nov.
  • For the diagnosis of B and T non-Hodgkin's lymphoma (NHL), thymoma, carcinoma and benign lesions of lymph node, the concordance between FCI data and morphological diagnosis were 93.5%, 100%, 100%, 100% and 81.3%, respectively.
  • CONCLUSION: Multi-parameter FCI analysis can provide important information and help for diagnosis of lymphoma.
  • It is an assistant but necessary approach for the diagnosis and differential diagnosis of lymphoma.
  • [MeSH-major] Flow Cytometry. Immunophenotyping / methods. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399172.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol; 2009 Mar 10;27(8):1209-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of deferred initial therapy in mantle-cell lymphoma.
  • PURPOSE: Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis.
  • Prognostic factors in assessable patients included advanced stage (III/IV) in 75%, elevated lactate dehydrogenase in 25%, and intermediate- or high-risk Mantle Cell International Prognostic Index in 54%.
  • [MeSH-major] Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prognosis. Treatment Outcome. Vincristine / administration & dosage


17. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 11 / genetics. Cytogenetic Analysis. Fatal Outcome. Follow-Up Studies. Histone-Lysine N-Methyltransferase. Humans. Male. Myeloid-Lymphoid Leukemia Protein / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


18. Feng H, Langenau DM, Madge JA, Quinkertz A, Gutierrez A, Neuberg DS, Kanki JP, Look AT: Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. Br J Haematol; 2007 Jul;138(2):169-75
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish.
  • The zebrafish is an ideal vertebrate model system to investigate the complex genetic basis of cancer because it has the capacity for in vivo tumour-cell imaging and forward genetic screens, and the molecular mechanisms regulating malignancy are remarkably conserved when compared with human.
  • Our laboratory has previously generated transgenic zebrafish models that overexpress the mouse c-Myc gene fused to enhanced green fluorescent protein (EGFP) and develop T-cell acute lymphoblastic leukaemia (T-ALL) that recapitulates the human disease both molecularly and pathologically.
  • After heat-shock treatment at 3 d postfertilisation (dpf) for 45 min at 37 degrees C, 81% of compound transgenic fish developed T-lymphoblastic lymphoma (T-LBL, mean latency 120 +/- 43 (standard deviation) days of life), which rapidly progressed to T-ALL.
  • [MeSH-major] HSP70 Heat-Shock Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593023.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-119066; United States / NCI NIH HHS / CA / CA-68484; United States / NHLBI NIH HHS / HL / T32-HL007574
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / HSP70 Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


19. Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA: Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev; 2006 Apr;15(4):630-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study.
  • Because lymphoma comprises numerous histologic subtypes, understanding the reasons for ongoing increases in its incidence requires surveillance and etiologic study of these subtypes.
  • Studies including patients diagnosed before 2001 may have codes from earlier ICD-O versions that must be converted to ICD-O-3 and have higher proportions of unclassified (e.g., lymphoma and not otherwise specified) cases.
  • To better understand (a) the agreement of computer-converted ICD-O-3 codes to ICD-O-3 codes generated directly from diagnostic pathology reports and (b) the reproducibility of unclassified status, we reviewed a population-based series of diagnostic pathology reports for lymphoma patients diagnosed before (1988-1994; n = 1,493) and after (1998-2000; n = 1,527) the REAL/WHO scheme was introduced.
  • The most common lymphoma subtypes, diffuse large B cell and follicular, had relatively good reliability (84-89%) throughout the study period.
  • T-cell and natural killer cell lymphomas had worse agreement than B-cell lymphomas, even when grouped.
  • These findings suggest that the study of lymphoma subtypes could be improved by (a) use of more standardized terminology in pathology reports, (b) grouping individual ICD-O-3 codes to reduce misclassification bias, and (c) routine secondary editing of unclassified lymphomas by central cancer registries.
  • [MeSH-major] Lymphoma / classification. Lymphoma / epidemiology. Population Surveillance / methods. SEER Program
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. International Classification of Diseases. Male. Middle Aged. Registries. Reproducibility of Results. San Francisco / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614102.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA45614; United States / NCI NIH HHS / CA / CA66529; United States / NCI NIH HHS / CA / CA89745; United States / NCI NIH HHS / CN / N01-CN-65107
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


20. Kim HY, Oh SY, Lee S, Lee DM, Kim SH, Kwon HC, Hong SH, Yoon JH, Kim HJ: Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy. Acta Haematol; 2008;120(3):150-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy.
  • Primary penile lymphoma is rarely observed in cases of extranodal malignant lymphoma.
  • Histopathological examination of the excisional biopsy revealed CD20+ diffuse large B cell lymphoma.
  • The patient was classified as having a stage I(AE) lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / therapy. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19039206.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


21. Mani D, Guinee DG Jr, Aboulafia DM: AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma. World J Gastroenterol; 2008 Jul 21;14(27):4395-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma.
  • Plasmablastic lymphoma (PBL) is a rare form of diffuse large B-cell lymphoma characterized by weak/absent expression of conventional B-cell markers and strong expression of plasma cell markers.
  • However, gene rearrangement studies confirmed a B-cell process and a more detailed immunohistochemical analysis revealed the cells stained positively for CD138 (plasma cell antigen).
  • [MeSH-major] Esophageal Neoplasms / complications. Esophageal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Medical Oncology / methods. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / biosynthesis. Antigens, CD38 / biosynthesis. Cell Differentiation. Diagnosis, Differential. Endoscopy / methods. Gene Rearrangement. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Male. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Histopathology. 2007 Dec;51(6):774-7 [17944927.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540 [15489661.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oncologist. 2006 Jun;11(6):666-73 [16794245.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):80-1 [17213349.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1358-61 [17577502.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Hepatology. 2007 Jul;46(1):107-12 [17526021.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3176-8 [17634499.001]
  • [Cites] AIDS Read. 2007 Sep;17(9):446-7 [17902226.001]
  • [Cites] AIDS Read. 2007 Sep;17(9):448-9 [17902227.001]
  • [Cites] Oral Dis. 2007 Nov;13(6):564-9 [17944673.001]
  • [Cites] Rev Soc Bras Med Trop. 2007 Sep-Oct;40(5):582-4 [17992417.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • (PMID = 18666332.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC2731195
  •  go-up   go-down


22. Israel R, Dorer R, Aboulafia DM: Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy. Am J Med Sci; 2010 Feb;339(2):185-7
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy.
  • As the incidence of human immunodeficiency virus (HIV) infection in women of child bearing age continues to increase in the era of highly active antiretroviral therapy and Hodgkin lymphoma (HL) is the most common non-acquired immunodeficiency syndrome defining malignancy, we anticipate that the number of cases of HIV-associated HL in pregnant women will increase in the near future.
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Humans. Viral Load


23. Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J: Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res; 2005 Jul 15;11(14):5215-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
  • EXPERIMENTAL DESIGN: Cohorts of three to six patients with B-cell lymphoma received 185 MBq/m2 [90Y]epratuzumab with unconjugated epratuzumab (total protein dose 1.5 mg/kg) once weekly for two to four infusions, with [(111)In]epratuzumab coadministered at first infusion for scintigraphic imaging and dosimetry.
  • Of 13 patients with tumor cell CD22 expression determined by flow cytometry, seven of eight with strongly positive results had objective responses, versus one of five with negative or weakly positive results (P = 0.032).
  • CONCLUSIONS: Radioimmunotherapy with weekly 185 MBq/m2 [90Y]epratuzumab achieved a high objective response rate (62%) across lymphoma subtypes, including durable CRs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Cell Adhesion Molecules / biosynthesis. Disease-Free Survival. Female. Gene Expression Profiling. Humans. Infusions, Intravenous. Lectins / biosynthesis. Male. Middle Aged. Radioimmunotherapy. Sialic Acid Binding Ig-like Lectin 2. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033839.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


24. Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ: Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. Head Neck Pathol; 2010 Sep;4(3):181-91
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
  • Primary lymphomas of the oral cavity are rare and the most frequent type is diffuse large B-cell lymphoma (DLBCL).
  • Recently, several reports have highlighted the value of classifying DLBCL into prognostically important subgroups, namely germinal center B-cell like (GCB) and non-germinal center B-cell like (non-GCB) lymphomas based on gene expression profiles and by immunohistochemical expression of CD10, BCL6 and MUM-1.
  • IHC was performed using antibodies against germinal center markers (CD10, BCL6), activated B-cell markers (MUM1, BCL2) and Ki-67 (proliferation marker).
  • [MeSH-major] Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Disease-Free Survival. Fatal Outcome. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):117-22 [9894462.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):423-9 [10458261.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):545-51 [15517363.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):398-405 [15492762.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):247-57 [16342164.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1521-7 [16998463.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Hematology. 2009 Apr;14(2):84-9 [19298719.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1842-7 [19656156.001]
  • [Cites] Mod Pathol. 2010 Feb;23(2):235-43 [19935644.001]
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1244-52 [11106083.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1089-98 [11697626.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] J Pathol. 1988 Mar;154(3):223-35 [2450981.001]
  • [Cites] J Clin Pathol. 1989 Nov;42(11):1194-200 [2531171.001]
  • [Cites] Am J Pathol. 1990 Aug;137(2):225-32 [2201196.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):231-6 [8508412.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1993 Oct 29;262(5134):747-50 [8235596.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):807-16 [12181265.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1366-73 [12481019.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1269-77 [12960812.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):25-30 [3296898.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):121-5 [8032301.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1543-55 [8623923.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):173-8 [8863307.001]
  • (PMID = 20533006.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2923304
  •  go-up   go-down


25. Plaisier MB, Sie-Go DM, Berendschot TT, Petersen EJ, Mourits MP: Ocular adnexal lymphoma classified using the WHO classification: not only histology and stage, but also gender is a predictor of outcome. Orbit; 2007 Jun;26(2):83-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular adnexal lymphoma classified using the WHO classification: not only histology and stage, but also gender is a predictor of outcome.
  • MALT lymphoma appears to be the most frequent OAL.
  • Of those with primary OAL, 27 had MALT, eight diffuse large B-cell, six mantle cell and eight follicular cell lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification. Orbital Neoplasms / classification
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Eyelids / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care). Predictive Value of Tests. Prognosis. Proportional Hazards Models. Sex Factors. Survival Analysis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613853.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol; 2009 Jul 10;27(20):3354-62
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
  • RESULTS: Diffuse large B-cell lymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were all over-represented in the SOT population compared with a population sample from the Surveillance, Epidemiology, and End Results (SEER) database; follicular lymphoma (n = 0) was underrepresented.
  • Extralymphatic disease (79%), poor performance status (68%), elevated lactate dehydrogenase (LDH; 71%), and advanced stage (68%) disease were all common at the time of lymphoma diagnosis.
  • Follicular lymphoma is unusual.
  • [MeSH-major] Lymphoma / etiology. Lymphoproliferative Disorders / etiology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. Immunohistochemistry. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. In Situ Hybridization. Kaplan-Meier Estimate. Male. Michigan. Middle Aged. RNA, Viral / genetics. Risk Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use. Treatment Outcome. Viral Matrix Proteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Immunosuppressive Agents; 0 / RNA, Viral; 0 / Viral Matrix Proteins; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


27. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


28. Pilichowska ME, Smouse JH, Dorfman DM: Concurrent herpes simplex viral lymphadenitis and mantle cell lymphoma: a case report and review of the literature. Arch Pathol Lab Med; 2006 Apr;130(4):536-9
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent herpes simplex viral lymphadenitis and mantle cell lymphoma: a case report and review of the literature.
  • We report a case of localized herpes simplex virus lymphadenitis in a patient with mantle cell lymphoma (MCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Herpes Simplex / pathology. Lymphadenitis / pathology. Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antiviral Agents / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Ganciclovir / therapeutic use. Humans. Neoplasm Staging. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594747.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P9G3CKZ4P5 / Ganciclovir; CVAD protocol
  •  go-up   go-down


29. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol; 2006 Aug 20;24(24):3880-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
  • PURPOSE: A multicenter, single-arm study examining efficacy and toxicity of epratuzumab combined with rituximab was conducted in patients with recurrent or refractory non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Sixty-five patients were enrolled; 34 patients with follicular lymphoma (FL), 15 patients with diffuse large B-cell lymphoma (DLBCL), and 16 patients with other lymphomas.
  • Two of six patients with marginal zone lymphoma responded to treatment (one CR).
  • There was a trend for the response rates to be higher in patients with low prognostic index scores (statistically significant with respect to the Follicular Lymphoma International Prognostic Index score in FL patients), with 12 FL patients and three DLBCL patients in groups 0 to 1 having OR (CR/CRu) rates of 83% (33%) and 100% (100%), respectively.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, B-Cell / drug therapy. Sialic Acid Binding Ig-like Lectin 2 / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Drug Administration Schedule. Europe. Female. Humans. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Ochenrider MG, Patterson DJ, Aboulafia DM: Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):144-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of peripheral T-cell lymphoma.
  • He died 7 months after diagnosis from chemotherapy-refractory lymphoma.
  • [MeSH-major] Antibodies, Monoclonal. Crohn Disease / drug therapy. Liver Neoplasms / chemically induced. Lymphoma, T-Cell / chemically induced. Splenic Neoplasms / chemically induced
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adalimumab. Adolescent. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Azathioprine / therapeutic use. Fatal Outcome. Humans. Infliximab. Leukemia-Lymphoma, Adult T-Cell / chemically induced. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Male. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371449.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; E7WED276I5 / 6-Mercaptopurine; FYS6T7F842 / Adalimumab; MRK240IY2L / Azathioprine
  • [Number-of-references] 24
  •  go-up   go-down


31. Freedman DM, Kimlin MG, Hoffbeck RW, Alexander BH, Linet MS: Multiple indicators of ambient and personal ultraviolet radiation exposure and risk of non-Hodgkin lymphoma (United States). J Photochem Photobiol B; 2010 Dec 2;101(3):321-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple indicators of ambient and personal ultraviolet radiation exposure and risk of non-Hodgkin lymphoma (United States).
  • Recent epidemiologic studies have suggested that ultraviolet radiation (UV) may protect against non-Hodgkin lymphoma (NHL), but few, if any, have assessed multiple indicators of ambient and personal UV exposure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Ultraviolet Rays
  • [MeSH-minor] Adult. Aged. Female. Humans. Logistic Models. Male. Middle Aged. Odds Ratio. Risk Factors. Surveys and Questionnaires. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • [Cites] Int J Biometeorol. 2000 Nov;44(4):186-9 [11131290.001]
  • [Cites] Cancer Causes Control. 2010 Aug;21(8):1265-75 [20373010.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):298-300 [8614009.001]
  • [Cites] BMJ. 1997 May 17;314(7092):1451-5 [9167561.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):161-3 [15687354.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Int J Epidemiol. 2006 Apr;35(2):495-7 [16330477.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] J Photochem Photobiol B. 2007 Mar 1;86(3):234-9 [17142054.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Am J Epidemiol. 2007 Jun 1;165(11):1255-64 [17327216.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 18;99(14):1120-9 [17623801.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1031-7 [17653828.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Int J Epidemiol. 2008 Oct;37(5):1080-94 [18511490.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):464-71 [19190171.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1569-76 [20501763.001]
  • [Cites] Photochem Photobiol. 2010 May-Jun;86(3):481-91 [20550646.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):429-34 [15095310.001]
  • (PMID = 20826094.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010133-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS235067; NLM/ PMC2963689
  •  go-up   go-down


32. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE: Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol; 2006 Jul;19(7):891-8
GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation.
  • B-cell lymphoma 10 (BCL-10) is expressed in the cytoplasm of normal germinal center and marginal zone B-cells and is involved in lymphocyte development and activation.
  • Aberrant nuclear expression of BCL-10 occurs in a subset of extranodal marginal zone B-cell lymphomas (MALT lymphomas), primarily those with the t(1;14)(p22;q32) or t(11;18)(q21;q21).
  • Little is known about BCL-10 expression in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM).
  • These results indicate that nuclear BCL-10 expression is common in LPL/WM and does not correlate with MALT lymphoma-associated translocations or p65 NF-kappaB nuclear staining.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Bone Marrow / metabolism. Cell Nucleus / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Transcription Factor RelA / metabolism. Waldenstrom Macroglobulinemia / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Female. Humans. Immunoglobulin M / blood. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636680.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / Immunoglobulin M; 0 / RELA protein, human; 0 / Transcription Factor RelA
  •  go-up   go-down


33. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT: Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant; 2008 Jan;14(1):59-66
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
  • Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients.
  • High-dose chemotherapy and autologous stem cell transplantation (AuSCT), moreover, has resulted in sustained complete remissions in selected patients with recurrent chemosensitive disease.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158962.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01CA083216; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / R01 CA095423; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01CA083035; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  • [Other-IDs] NLM/ NIHMS281894; NLM/ PMC4524737
  •  go-up   go-down


34. Barclay LR, Buskin SE, Kahle EM, Aboulafia DM: Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma Myeloma; 2007 Jan;7(4):272-9
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Despite the decrease in HIV-associated morbidity and mortality with the advent of highly active antiretroviral therapy (HAART), the incidence of AIDS-related lymphoma (ARL) has not decreased as significantly.
  • We used the Adult and Adolescent Spectrum of HIV-Related Diseases database of Public Health-Seattle and King County to determine incidences and trends among patients with ARL in Seattle/King County, WA.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324334.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 30
  •  go-up   go-down


35. Pomerantz RG, Campbell LS, Jukic DM, Geskin LJ: Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Arch Dermatol; 2010 May;146(5):513-6
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk.
  • BACKGROUND: Cutaneous T-cell lymphoma occurring in the context of posttransplant immunosuppression is rare, with 27 cases documented to date.
  • OBSERVATIONS: We report 2 new cases of posttransplant cutaneous T-cell lymphoma in patients treated at our institution.
  • CONCLUSIONS: These cases underscore the association of posttransplant cutaneous T-cell lymphoma with renal transplantation, cyclosporine and tacrolimus therapy, male sex, and later onset compared with B-cell posttransplant lymphoproliferative disease.
  • Relative to the general population, the incidence of cutaneous T-cell lymphoma seems increased among transplant recipients receiving immunosuppressive medications.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Kidney Transplantation / methods. Lymphoma, T-Cell, Cutaneous / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Calcineurin Inhibitors. Cyclosporine / adverse effects. Cyclosporine / therapeutic use. Humans. Male. Risk Factors. Sex Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479299.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


36. Ma J, Liu YF, Chen SM, Zhang QT, Sun L, Liu LX, Wan DM, Chen SQ, Xie XS, Meng XL, Jiang ZX, Cheng YD, Wang F, Sun H: [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):942-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages].
  • The purpose of this study was to investigate the immunophenotyping characteristics of adult acute lymphoblastic leukemia (ALL) patients in groups of different ages.
  • The results indicated that (1) all the 82 cases of T-cell acute lymphoblastic leukemia (T-ALL) expressed CD7 (100%) while the positive rate of CD2 remarkably decreased with aging.
  • Moreover, there were significant differences of the myeloid antigen (MyAg) and CD13 expression between the older adults and younger adults (p < 0.05). (2) As to adult B-cell acute lymphoblastic leukemia (B-ALL), the positive rates of CD19 and HLA-DR in 178 cases were 100%; the positive rate of CD33 in young adults was significant higher than that in adolescents (p < 0.05), the differences of the other marker expressions failed to reach statistical significance in adult B-ALL patients.
  • It is concluded that the immunophenotypes of adult T-ALL are evidently heterogeneous in different ages, and expression with more aberrant phenotypes indicates poor prognostic significance in patients older than 35 years.
  • There is no significant association of immunophenotypes with ages among different age groups of adult B-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723305.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD2; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


37. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED: Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol; 2008 Oct 10;26(29):4814-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
  • PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.
  • Unlike systemic diffuse large B-cell lymphoma, del(6)(q22) is common and IGH translocations are infrequent and usually involve BCL6 rather than BCL2, suggesting a distinct pathogenesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82 [16896311.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51 [12640061.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):164-9 [12802586.001]
  • [Cites] Cerebrovasc Dis. 2004;17(2-3):224-7 [14707426.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1757-9 [8142643.001]
  • [Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Blood. 1995 May 15;85(10):2877-84 [7742550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2466-72 [16240449.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1445-51 [10550299.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7 [10942021.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):147-50 [11369058.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • (PMID = 18645192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2653136
  •  go-up   go-down


38. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol; 2005 Jul 1;23(19):4390-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
  • PURPOSE: This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma.
  • PATIENTS AND METHODS: Patients had follicular lymphoma that had relapsed or failed to respond to primary therapy; the majority (90%) presented with stage III or IV disease.
  • CONCLUSION: The favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD80 / immunology. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Infection / complications. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994148.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD80; 0 / Antineoplastic Agents; 357613-77-5 / galiximab
  •  go-up   go-down


39. Combs S, Neil N, Aboulafia DM: Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study. Oncologist; 2006 Jun;11(6):666-73
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study.
  • PURPOSE: To evaluate in a pilot study the safety and efficacy of liposomal doxorubicin, cyclophosphamide, and etoposide (LACE) when combined with antiretroviral therapy (ART) in patients with AIDS-related lymphoma (ARL).
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Carriers. Etoposide / administration & dosage. Female. Humans. Liposomes. Male. Middle Aged. Pilot Projects. Survival Rate. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794245.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Drug Carriers; 0 / Liposomes; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1
  •  go-up   go-down


40. Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, Tamaki Y, Matsumoto M, Hirabayashi K, Igarishi S, Masawa N, Nakamura S: Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int J Surg Pathol; 2006 Jan;14(1):43-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases.
  • We conducted clinicopathologic and immunohistochemical analyses of the prevalence of Epstein-Barr virus (EBV) among 24 patients with malignant lymphoma complicating systemic rheumatic diseases. (SRD) These 24 patients included 17 with rheumatoid arthritis (RA), 3 with systemic lupus erythematosus (SLE), 2 with systemic sclerosis (SS), and 2 with dermatomyositis (DM).
  • The use of immunosuppressive drugs before the onset of malignant lymphoma was recorded in 15 patients.
  • Histologic and immunohistochemical studies demonstrated that 18 cases (75%) were B-cell lymphoma (RA=12, SLE=2, SS=2, DM=2), 3 (12.5%) were peripheral T-cell lymphoma (RA=3), and 3 (12.5%) were classical Hodgkin lymphoma (RA=2, SLE=1).
  • As in previous reports, there was an increased frequency of diffuse large B-cell lymphoma (50%) in the present series.
  • Moreover, a majority of the diffuse large B-cell lymphomas exhibited activated B-cell phenotype.
  • Our findings suggested EBV-associated lymphoma comprised only a small fraction of all non-Hodgkin's lymphomas in the general SRD patient population.
  • [MeSH-major] Lymphoma / complications. Rheumatic Diseases / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / pathology. Dermatomyositis / complications. Dermatomyositis / pathology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / epidemiology. Epstein-Barr Virus Infections / pathology. Female. Herpesvirus 4, Human / genetics. Hodgkin Disease / complications. Hodgkin Disease / pathology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Japan. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology. Male. Middle Aged. RNA, Viral / analysis. Scleroderma, Systemic / complications. Scleroderma, Systemic / pathology


41. Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N, Chaplin T, Lillington DM, Lister TA, Young BD: Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A; 2008 May 06;105(18):6708-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.
  • Importantly, the pattern of deletions resembled that recently reported in pediatric ALL, suggesting that adult, adolescent, and childhood cases may be more similar on the genetic level than previously thought.
  • Our findings provide insights into the leukemogenic process and may be clinically important in adult and adolescent ALL.
  • [MeSH-major] Gene Deletion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Cell Cycle / genetics. Child. Chromosome Aberrations. Genes, Neoplasm. Genome, Human / genetics. Humans. Lymphopoiesis / genetics. Middle Aged. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):176-8 [16213368.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2006 May;20(5):840-6 [16498392.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):748-56 [16470520.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8 [17311819.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2327-30 [17095619.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Cancer. 2007 May 15;109(10):2058-67 [17407135.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4306-18 [17237825.001]
  • [Cites] Hum Mol Genet. 2007 Sep 15;16(18):2215-25 [17613536.001]
  • [Cites] Immunol Cell Biol. 2008 Jan;86(1):47-53 [17998914.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):729-39 [18506749.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1976-82 [11064355.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Ann Med. 2004;36(7):492-503 [15513300.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Jul;16(3):155-63 [8814447.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • (PMID = 18458336.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE9611
  • [Grant] United Kingdom / Cancer Research UK / / A6438; United Kingdom / Cancer Research UK / / A6789
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373322
  •  go-up   go-down


42. Galor A, Ference SJ, Singh AD, Lee MS, Stevens GH, Perez VL, Peereboom DM: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. Am J Ophthalmol; 2007 Jul;144(1):45-49
Hazardous Substances Data Bank. D-MANNITOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
  • PURPOSE: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma.
  • METHODS: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic.
  • CONCLUSIONS: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Lymphoma / drug therapy. Mannitol / adverse effects. Methotrexate / adverse effects. Retinal Diseases / chemically induced
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carotid Artery, Internal. Catheterization, Peripheral. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Fluorescein Angiography. Humans. Injections, Spinal. Male. Middle Aged. Pigment Epithelium of Eye / drug effects. Pigment Epithelium of Eye / pathology. Retrospective Studies. Tomography, Optical Coherence. Vertebral Artery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2007 Dec;144(6):976; author reply 976 [18036877.001]
  • (PMID = 17601426.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 3OWL53L36A / Mannitol; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


43. Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, Eiser C, Coleman RE, Ross RJ: High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. Br J Cancer; 2006 Feb 27;94(4):469-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.
  • Assessment of late effects in a cohort of female Hodgkin's lymphoma patients treated with mantle radiotherapy, identified from the DoH breast cancer screening recall showed high mortality and frequent undiagnosed abnormalities in tissues affected by radiotherapy.
  • [MeSH-minor] Adult. Breast Neoplasms / diagnosis. Female. Follow-Up Studies. Humans. Incidence. Mass Screening. Middle Aged. Morbidity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):498-509 [10653865.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 4:115-26 [8836422.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):536-44 [9469338.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):240-8 [9473759.001]
  • [Cites] Haematologica. 1998 Sep;83(9):812-23 [9825578.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):418-24 [16106249.001]
  • [Cites] Lancet Oncol. 2003 Apr;4(4):207-14 [12681264.001]
  • [Cites] JAMA. 2003 Jul 23;290(4):465-75 [12876089.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):294-8 [14735166.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [Cites] Acta Haematol. 2004;112(3):148-51 [15345897.001]
  • [Cites] Ann Intern Med. 2004 Oct 19;141(8):590-7 [15492338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1925-31 [3932270.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):355-63 [2261376.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):908-12 [1616862.001]
  • [Cites] Ann Oncol. 1992 Jun;3(6):455-61 [1498064.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] N Engl J Med. 1996 Mar 21;334(12):745-51 [8592547.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • (PMID = 16465193.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361189
  •  go-up   go-down


44. Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, Severson RK, Davis S: Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control; 2006 Oct;17(8):1045-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States).
  • OBJECTIVE: Because of conflicting findings about the relationship between ultraviolet (UV) radiation and the risk of non-Hodgkin lymphoma (NHL), we evaluated the risk of several indicators related to UV, including two not previously studied: dietary vitamin D, and ambient UV levels by residential location.
  • Effects were generally similar for diffuse large B-cell (DLBCL) and follicular lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Ultraviolet Rays. Vitamin D / administration & dosage. Vitamin D / pharmacology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Confidence Intervals. Female. Humans. Interviews as Topic. Male. Middle Aged. Risk Factors. Surveys and Questionnaires. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933055.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / PC / N02-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


45. Alm El-Din MA, Hughes KS, Finkelstein DM, Betts KA, Yock TI, Tarbell NJ, Aisenberg AC, Taghian AG: Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):69-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter.
  • PURPOSE: To evaluate the risk of breast cancer (BC) and the contributing risk factors in women after supradiaphragmatic irradiation (SDI) for Hodgkin's lymphoma (HL).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Comorbidity. Female. Humans. Incidence. Massachusetts / epidemiology. Middle Aged. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538497.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


47. Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC: Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol; 2010 Jul;150(2):189-95
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
  • Targeting aberrant DNA hypermethylation in chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) with decitabine may reverse epigenetic silencing in B-cell malignancies.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):87-91 [12708480.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2424-33 [15059895.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2928-35 [15131027.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4347-53 [10361133.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):265-74 [15723065.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3877-85 [15809452.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] Br J Cancer. 2005 Dec 12;93(12):1388-94 [16333246.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(7):1117-26 [16523529.001]
  • [Cites] Haematologica. 2006 Jul;91(7):895-902 [16818276.001]
  • [Cites] Blood. 2007 Jan 1;109(1):52-7 [16882708.001]
  • [Cites] Nucleic Acids Res. 2007;35(5):e31 [17264127.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):857-65 [18078872.001]
  • [Cites] Blood. 2009 Jan 15;113(3):659-67 [18931345.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3881-8 [19470736.001]
  • (PMID = 20456354.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109004-01A1; United States / NCI NIH HHS / CA / P01 CA101956; United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / U01 CA076576; United States / NCI NIH HHS / CA / K23 CA109004; United States / NCI NIH HHS / CA / P30 CA016058; None / None / / K23 CA109004-01A1; United States / NCI NIH HHS / CA / U01 CA76576
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS216448; NLM/ PMC2917115
  •  go-up   go-down


48. Proca DM, De Renne L, Marsh WL Jr, Keyhani-Rofagha S: Anaplastic large cell lymphoma in a human immunodeficiency virus-positive patient with cytologic findings in bladder wash: a case report. Acta Cytol; 2008 Jan-Feb;52(1):83-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in a human immunodeficiency virus-positive patient with cytologic findings in bladder wash: a case report.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) (Ki-1/CD-30 positive) is an uncommon lymphoproliferative disorder that may be of T cell or null cell type.
  • The ALCL was CD30+ and null cell type, with negative CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD45, CD79a, ALK-1, granzyme B, cytokeratin (AE1/AE3), placental alkaline phosphatase (PLAP) and S-100.
  • CONCLUSION: This is a rare occurrence of ALCL (CD 30 positive, null cell type) in the urinary bladder in an HIV+ patient.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis. Urinary Bladder / pathology
  • [MeSH-minor] Adult. Humans. Male


49. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM: High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol; 2010 Aug 10;28(23):3709-16
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
  • PURPOSE: Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: A multicenter trial evaluated two or three weekly infusions of yttrium-90 ((90)Y) epratuzumab tetraxetan (humanized anti-CD22 antibody) in 64 patients with relapsed/refractory NHL, including 17 patients who underwent prior autologous stem-cell transplantation (ASCT).
  • For patients with follicular lymphoma (FL), OR rates and median PFS increased with total (90)Y-dose, reaching 100% (CR/CRu, 92%) and 24.6 months, respectively, at the highest dose levels (> 30 mCi/m(2) total (90)Y-dose [1,110 MBq/m(2)]).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


50. Aboulafia DM, Puswella AL: Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS; 2007 Dec;21(12):900-7
HIV InSite. treatment guidelines - Symptom Management .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment.
  • A brain imaging study showed a right temporal mass, which on biopsy proved to be primary central nervous system lymphoma (PCNSL).
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male


51. Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP: Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol; 2008 Jul;19(7):1327-30
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
  • BACKGROUND: Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3-4 years.
  • Single-center studies with R-Hyper-CVAD and/or autologous stem-cell transplant (ASCT) have produced 3-year OS rates >80%, prompting many to adopt their use.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349031.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


52. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol; 2010 Nov;21(11):2246-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
  • BACKGROUND: Based on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):1165-74 [18383361.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):96-100 [11823707.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3736-42 [12097283.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):311-5 [12201493.001]
  • [Cites] Thyroid. 2003 Mar;13(3):259-63 [12729474.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] J Immunother. 2004 Sep-Oct;27(5):347-53 [15314543.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2635-42 [15226177.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2083-7 [2566368.001]
  • [Cites] Arch Pathol Lab Med. 1992 Nov;116(11):1197-201 [1332642.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3378-404 [7780126.001]
  • [Cites] Cell. 1996 Feb 23;84(4):551-62 [8598042.001]
  • [Cites] Nature. 1999 Mar 25;398(6725):341-4 [10192335.001]
  • [Cites] Immunol Rev. 1999 Jun;169:23-9 [10450505.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1648-55 [16049514.001]
  • [Cites] Respir Res. 2005;6:81 [16042790.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jan;117(1):204-11 [16387607.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):353-60 [16329112.001]
  • [Cites] J Heart Lung Transplant. 2006 Apr;25(4):416-9 [16563971.001]
  • [Cites] Immunology. 2006 Jun;118(2):143-52 [16771849.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1596-601 [17198242.001]
  • [Cites] Haematologica. 2007 Jan;92(1):35-41 [17229633.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Clin Exp Immunol. 2007 Mar;147(3):472-82 [17302896.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2225-33 [17068147.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):434-40 [17409896.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):916-9 [17597477.001]
  • [Cites] Transpl Immunol. 2008 Jan;18(3):260-3 [18047935.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4370-2 [17909075.001]
  • [Cites] Eur J Dermatol. 2008 Jan-Feb;18(1):41-9 [18086588.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • (PMID = 20423913.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA07968
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / FCGR3A protein, human; 0 / Receptors, IgG; 0 / SGN-30 monoclonal antibody; 0 / liposomal doxorubicin; 0W860991D6 / Deoxycytidine; 30IQX730WE / Polyethylene Glycols; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2962257
  •  go-up   go-down


53. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC: A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia; 2009 May;23(5):912-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-alpha (TNF-alpha) release that can cause CLL proliferation and inhibit apoptosis.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Haematologica. 2006 Jun;91(6 Suppl):ECR23 [16785126.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68 [17707833.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1962-3 [10561242.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] Blood Cells Mol Dis. 2000 Apr;26(2):133-43 [10753604.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):203-10 [10962531.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):237-42 [12203106.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):36-8 [12517774.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1259-63 [7999409.001]
  • [Cites] Blood. 1995 Jan 15;85(2):307-18 [7811987.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):5038-45 [7594512.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):127-35 [9107564.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4342-9 [9596683.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Immunol Methods. 2005 Sep;304(1-2):88-99 [16109421.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):266-72 [16755224.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • (PMID = 19225537.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / P01 CA9542
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; OP401G7OJC / Etanercept; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS79899; NLM/ PMC4099250
  •  go-up   go-down


54. Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA: A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Dec 1;12(23):7046-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
  • PURPOSE: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Interleukin-2 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / genetics. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Injections, Intravenous. Injections, Subcutaneous. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Polymorphism, Genetic / genetics. Receptors, IgG / genetics. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145827.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K01 CA95426-01A1; United States / NCI NIH HHS / CA / K08 CA93518-01; United States / NCI NIH HHS / CA / K23 CA102155
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / FCGR3A protein, human; 0 / Fc gamma receptor IIA; 0 / Interleukin-2; 0 / Receptors, IgG; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


55. Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, Goldenberg DM, Bardiès M: Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer; 2010 Feb 15;116(4 Suppl):1093-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
  • [MeSH-major] Bone Marrow / radiation effects. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Radiometry / methods. Radiotherapy Dosage. Yttrium Radioisotopes / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20127958.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


56. Robison LL, Green DM, Hudson M, Meadows AT, Mertens AC, Packer RJ, Sklar CA, Strong LC, Yasui Y, Zeltzer LK: Long-term outcomes of adult survivors of childhood cancer. Cancer; 2005 Dec 1;104(11 Suppl):2557-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of adult survivors of childhood cancer.
  • The CCSS cohort has more than 14,000 active participants, including survivors of leukemia, brain tumors, Hodgkin disease, non-Hodgkin lymphoma, Wilms tumor, neuroblastoma, soft-tissue sarcoma, and bone tumors.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Cognition Disorders / etiology. Female. Health Knowledge, Attitudes, Practice. Humans. Longitudinal Studies. Male. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Pregnancy. Pregnancy Outcome. Quality of Life. Smoking

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247780.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


57. Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, Kamps WA, de Vries EG, Vellenga E: Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res; 2005 Dec 15;11(24 Pt 1):8661-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia.
  • [MeSH-major] Multidrug Resistance-Associated Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Child. Female. Gene Expression. Humans. Male. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. RNA, Neoplasm / chemistry. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361551.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


58. Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U, Maskarinec G, Rothman N, Shu XO, Stevens VL, Zeleniuch-Jacquotte A, Albanes D, Bertrand K, Weinstein SJ, Yu K, Irish L, Horst RL, Hoffman-Bolton J, Giovannucci EL, Kolonel LN, Snyder K, Willett W, Arslan AA, Hayes RB, Zheng W, Xiang YB, Hartge P: Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol; 2010 Jul 1;172(1):58-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
  • Case-control studies generally suggesting an inverse association between sun exposure and non-Hodgkin lymphoma (NHL) have led to speculation that vitamin D may protect against lymphomagenesis.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):132-9 [16595142.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Am J Epidemiol. 2007 Jun 1;165(11):1255-64 [17327216.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1634-47 [17641030.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1031-7 [17653828.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):979-86 [19035445.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Clin Biochem. 2009 Oct;42(15):1549-56 [19631201.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):10-20 [20562188.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):21-35 [20562191.001]
  • [Cites] Health Place. 1998 Dec;4(4):355-64 [10670982.001]
  • [Cites] Immunol Cell Biol. 2001 Dec;79(6):547-68 [11903614.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] Recent Results Cancer Res. 2003;164:371-7 [12899536.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):59-64 [14744734.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):255-65 [15090720.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • [Cites] Science. 1983 Sep 16;221(4616):1181-3 [6310748.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Dec;57(6):1308-10 [6313738.001]
  • [Cites] Br J Cancer. 1991 Mar;63(3):463-5 [2003990.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):668-72 [8398690.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):298-300 [8614009.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):945-50 [8611412.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1128-31 [8620128.001]
  • [Cites] Photochem Photobiol. 1996 Aug;64(2):254-8 [8760564.001]
  • [Cites] BMJ. 1997 May 17;314(7092):1451-5 [9167561.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):995-1009 [10354063.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • (PMID = 20562184.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CP / N02-CP-11010-66; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / PC / N01-PC35137; United States / NCI NIH HHS / CA / R37 CA70867; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / R37 CA070867; United States / NCI NIH HHS / CA / N01 CN25524; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA49449; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R37 CA54281; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CP / N02CP11010; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522; United States / NCI NIH HHS / CA / K07 CA73790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2892540
  •  go-up   go-down


59. Hu S, Granter SR, Haynes HA, Miller DM: Skin spicules: A newly described paraneoplastic phenomenon associated with a marginal zone B-cell lymphoma. J Am Acad Dermatol; 2009 May;60(5):852-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin spicules: A newly described paraneoplastic phenomenon associated with a marginal zone B-cell lymphoma.
  • We report an unusual variant of the sign of Leser-Trélat in a patient with a low-grade B-cell lymphoproliferative disorder and intertriginous skin spicules with histologic morphology of minute seborrheic keratoses.
  • [MeSH-major] Keratosis, Seborrheic / pathology. Lymphoma, B-Cell / pathology. Paraneoplastic Syndromes / pathology. Skin Diseases / pathology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389527.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE: HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol; 2007 Jan;20(1):54-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.
  • HDM4 expression in most cases of adult pre-B ALL suggests that HDM4 is a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / pathology. Nuclear Proteins / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Philadelphia Chromosome. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-mdm2 / analysis. RNA, Messenger / analysis. Time Factors. Treatment Outcome. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143258.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / MDM4 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


61. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol; 2006 Mar;126(3):575-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
  • Denileukin diftitox (Ontak), a recombinant fusion protein of diphtheria toxin and ligand, IL-2, binds to the IL-2 receptor, is internalized, and causes cell death.
  • Denileukin diftitox was approved for the treatment of cutaneous T-cell lymphomas (CTCLs) with CD25+ expression.
  • Advanced TNM (T3 or T4) was significantly associated with intermediate-grade (P = 0.002) and large-cell transformation histology (P = 0.04).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Receptors, Interleukin-2 / analysis. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD30 / analysis. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Recombinant Fusion Proteins / therapeutic use. Skin / pathology. Tetrahydronaphthalenes / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410787.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815; United States / NCI NIH HHS / CA / R21-CA74117
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 25E79B5CTM / denileukin diftitox; A61RXM4375 / bexarotene; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


62. Mulrooney DA, Ness KK, Neglia JP, Whitton JA, Green DM, Zeltzer LK, Robison LL, Mertens AC: Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS). Sleep; 2008 Feb;31(2):271-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS).
  • STUDY OBJECTIVE: To examine the prevalence of and risk factors for fatigue and sleep disturbance among adult survivors of childhood cancer.
  • PARTICIPANTS: Two thousand six hundred forty-five survivors of childhood acute lymphocytic leukemia, central nervous system tumors, Hodgkin lymphoma, soft-tissue sarcomas, or bone tumors diagnosed before age 21, surviving at least 5 years from diagnosis, and a 500-sibling comparison group.
  • CONCLUSION: Because of the large sample size, we detected more objectively reported fatigue, sleep disturbance, and daytime sleepiness among adult survivors of childhood cancer.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Jan;39(2):204-14 [12509953.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Oncologist. 2003;8 Suppl 1:5-9 [12626781.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1249-54 [12663711.001]
  • [Cites] J Pain Symptom Manage. 2003 Apr;25(4):307-18 [12691682.001]
  • [Cites] Pediatrics. 2003 Jul;112(1 Pt 1):e46-54 [12837905.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2179-86 [14522376.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):503-10 [15080780.001]
  • [Cites] Psychiatry Res. 1989 May;28(2):193-213 [2748771.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] J Pain Symptom Manage. 2000 Feb;19(2):91-9 [10699536.001]
  • [Cites] J Pain Symptom Manage. 2000 Jul;20(1):12-8 [10946164.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):971-5 [11038033.001]
  • [Cites] Support Care Cancer. 2001 Jan;9(1):11-7 [11147137.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):895-908 [11157043.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3385-91 [11454886.001]
  • [Cites] J Child Neurol. 2001 Oct;16(10):767-70 [11669353.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):528-38 [11900238.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3993-6 [12161549.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2431-41 [12436452.001]
  • [Cites] Sleep. 1991 Dec;14(6):540-5 [1798888.001]
  • [Cites] Neuropediatrics. 1992 Feb;23(1):39-45 [1565216.001]
  • [Cites] J Epidemiol Community Health. 1992 Apr;46(2):92-7 [1583440.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Sleep. 1992 Aug;15(4):376-81 [1519015.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):547-56 [9053476.001]
  • [Cites] J Pain Symptom Manage. 1997 Feb;13(2):63-74 [9095563.001]
  • [Cites] Support Care Cancer. 1998 Mar;6(2):101-8 [9540167.001]
  • [Cites] J Psychosom Res. 1998 Jul;45(1):5-13 [9720850.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):253-61 [10458240.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5501-10 [16110010.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6587-95 [16170166.001]
  • [Cites] Ann Intern Med. 2005 Nov 1;143(9):639-47 [16263886.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • (PMID = 18274275.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA 55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2225565
  •  go-up   go-down


63. Kurtz DM, Tschetter LK, Allred JB, Geyer SM, Kurtin PJ, Putnam WD, Rowland KM Jr, Wiesenfeld M, Soori GS, Tenglin RC, Bernath AM, Witzig TE: Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leuk Lymphoma; 2007 Jul;48(7):1290-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.
  • Interleukin-4 (IL-4), a pleiotropic cytokine, has in vitro activity against non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Interleukin-4 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Jul;48(7):1259-60 [17613750.001]
  • [CommentIn] Leuk Lymphoma. 2007 Jul;48(7):1261-3 [17613751.001]
  • (PMID = 17613756.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 207137-56-2 / Interleukin-4
  •  go-up   go-down


64. Dimitriadi M, Poulogiannis G, Liu L, Bäcklund LM, Pearson DM, Ichimura K, Collins VP: p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours. Br J Cancer; 2008 Oct 07;99(7):1144-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.
  • MDM2 encodes a nuclear phosphoprotein that regulates several cell proteins by binding and/or ubiquitinating them, with p53 being a well-established partner.
  • We used RT-PCR to study P1- and P2-MDM2 transcript expression in astrocytic tumours, xenografts and cell lines with known MDM2, TP53 and p14(ARF) gene status.
  • [MeSH-minor] Adult. Genotype. Humans. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1083-8 [10533452.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 May;47(5):203-8; discussion 208-9 [17527046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14517-22 [10588737.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2023-30 [10688649.001]
  • [Cites] Oncogene. 2000 Feb 10;19(6):831-5 [10698502.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):265-70 [10861503.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):587-96 [10934161.001]
  • [Cites] Cell. 2000 Oct 13;103(2):321-30 [11057904.001]
  • [Cites] Cancer Lett. 2001 Mar 26;164(2):177-88 [11179833.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1598-603 [11245471.001]
  • [Cites] Oncogene. 2001 May 31;20(25):3193-205 [11423969.001]
  • [Cites] Oral Oncol. 2001 Dec;37(8):620-31 [11590071.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):557-63 [11956627.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):1955-62 [11960368.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2616-23 [12750288.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25716-21 [12730202.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):1017-26 [14707285.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3536-51 [15060172.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29841-8 [15090541.001]
  • [Cites] Int Rev Exp Pathol. 1983;24:135-202 [6601641.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2736-9 [8504413.001]
  • [Cites] Genes Dev. 1994 Aug 1;8(15):1739-49 [7958853.001]
  • [Cites] Leuk Lymphoma. 1995 Mar;17(1-2):13-8 [7773150.001]
  • [Cites] Nucleic Acids Res. 1995 Jul 25;23(14):2584-92 [7651818.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3562-8 [9270029.001]
  • [Cites] Oncogene. 1998 Apr 30;16(17):2249-57 [9619834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] Nucleic Acids Res. 1998 Aug 1;26(15):3453-9 [9671804.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5061-5 [9823311.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):864-72 [9858609.001]
  • [Cites] Cell. 2004 Nov 24;119(5):591-602 [15550242.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3215-20 [17545525.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):303-12 [17936556.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):241-4 [17568997.001]
  • [Cites] Brain Res. 2008 Mar 10;1198:16-20 [18262501.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Feb;5(1):9-20 [15720185.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):181-93 [15770670.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):16651-8 [15723837.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2122-37 [16131611.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9582-7 [16230424.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1996-8 [16167062.001]
  • [Cites] J Mol Med (Berl). 2005 Nov;83(11):917-26 [16133418.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4183-93 [16501602.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):195-7 [16239061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1559-61 [16896050.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):563-5 [17096342.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4975-7 [17214373.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1317-23 [17322917.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • (PMID = 18781178.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2567066
  •  go-up   go-down


65. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ; 2009 Dec 08;339:b4606
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.
  • OBJECTIVES: To assess the incidence of and risks for congestive heart failure, myocardial infarction, pericardial disease, and valvular abnormalities among adult survivors of childhood and adolescent cancers.
  • PARTICIPANTS: 14,358 five year survivors of cancer diagnosed under the age of 21 with leukaemia, brain cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, neuroblastoma, soft tissue sarcoma, or bone cancer between 1970 and 1986.
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Case-Control Studies. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. United States. Young Adult

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Saf. 2000 Apr;22(4):263-302 [10789823.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):31-7 [3581032.001]
  • [Cites] Stat Med. 1990 May;9(5):505-14 [2190287.001]
  • [Cites] Am J Cardiol. 1975 Feb;35(2):216-20 [1119380.001]
  • [Cites] Chest. 1991 Mar;99(3):538-45 [1995208.001]
  • [Cites] Am J Hematol. 1991 Mar;36(3):217-8 [1705095.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] JAMA. 1991 Sep 25;266(12):1672-7 [1886191.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):182-8 [8004574.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):881-9 [8960517.001]
  • [Cites] Am J Med Sci. 1997 Dec;314(6):399-400 [9413345.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6 [15856486.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):153-9 [15900998.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):173-85 [15896910.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):324-32 [15714447.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7685-96 [16234530.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] J Clin Epidemiol. 2006 Aug;59(8):862-7 [16828682.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3635-43 [17704413.001]
  • [Cites] Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 [18512336.001]
  • [Cites] Curr Treat Options Oncol. 2008 Feb;9(1):51-66 [18363110.001]
  • [Cites] BMC Cancer. 2008;8:141 [18492236.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2319-27 [19364957.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1191-6 [10849532.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):429-47 [11139373.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Arch Intern Med. 2001 Jan 22;161(2):277-84 [11176744.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] JAMA. 2002 Apr 10;287(14):1832-9 [11939869.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):86-92 [12116055.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):743-9 [12932613.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1108-13 [14630607.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):769-73 [14990630.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):37-44 [15162142.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [CommentIn] BMJ. 2009;339:b4691 [19996460.001]
  • (PMID = 19996459.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24 CA 55727; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / 1K12RR023247; United States / NCI NIH HHS / CA / U24 CA055727-17; United States / NCRR NIH HHS / RR / K12 RR023247-05; United States / NCRR NIH HHS / RR / K12 RR023247
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3266843
  •  go-up   go-down


66. Davis JL, Miller DM, Ruiz P: Diagnostic testing of vitrectomy specimens. Am J Ophthalmol; 2005 Nov;140(5):822-829
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the usefulness of diagnostic tests that are performed on vitrectomy specimens from patients with suspected lymphoma or infection.
  • RESULTS: There were 28 patients (33 eyes) with suspected intraocular lymphoma and 50 patients (51 eyes) with suspected infection, which was subdivided into chronic endogenous endophthalmitis, atypical chorioretinitis, or chronic postoperative inflammation.
  • Vitreous testing led to a diagnosis in 48 of 78 patients (61.5%); 14 patients with a final diagnosis of lymphoma/leukemia, and 34 patients with a final diagnosis of infection.
  • For lymphoma, the PPV of cytologic evaluation was 100% and the NPV 60.9%.
  • CD22+ B lymphocytes >or=20% of total cells on cytofluorographic analysis had a PPV of 88% for lymphoma.
  • CONCLUSION: Diagnostic vitrectomy in selected patients with carefully planned testing is an effective means of supporting diagnoses in intraocular lymphoma, chronic intraocular infections, and atypical chorioretinitis.
  • Flow cytometry quantitates the percentages and ratios of various cell types and is helpful in contrasting intraocular lymphoma with immunologically mediated uveitis.
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / pathology. Bacteriological Techniques. CD4-CD8 Ratio. Diagnostic Techniques, Ophthalmological. Endophthalmitis / diagnosis. Endophthalmitis / microbiology. False Negative Reactions. Female. Flow Cytometry. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Middle Aged. Polymerase Chain Reaction. Predictive Value of Tests. Retrospective Studies. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2006 May;141(5):982; author reply 982-3 [16678533.001]
  • (PMID = 16310459.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Matos DM, Rizzatti EG, Garcia AB, Gallo DA, Falcão RP: Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase. Braz J Med Biol Res; 2006 Oct;39(10):1349-55
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase.
  • We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and before the beginning of any therapy.
  • The diagnosis of B-cell non-Hodgkin's lymphomas was based on cytological, histological, immunophenotypic, and molecular biology methods.
  • Comparison of chronic lymphocytic leukemia and mantle-cell lymphoma showed that the former presented a higher expression of CD11c and CD49c, and a lower expression of CD11b and CD49d adhesion molecules.
  • Comparison of chronic lymphocytic leukemia and marginal B-cell lymphoma showed that the former presented a higher expression of CD49c and a lower expression of CD11a, CD11b, CD18, CD49d, CD29, and CD54.
  • Finally, comparison of mantle-cell lymphoma and marginal B-cell lymphoma showed that marginal B-cell lymphoma had a higher expression of CD11a, CD11c, CD18, CD29, and CD54.
  • Thus, the CD49c/CD49d pair consistently demonstrated a distinct pattern of expression in chronic lymphocytic leukemia compared with mantle-cell lymphoma and marginal B-cell lymphoma, which could be helpful for the differential diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053842.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules
  •  go-up   go-down


68. Gonçalves TL, Benvegnú DM, Bonfanti G: Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev; 2009 Apr-Jun;2(2):82-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.
  • Successful hematopoietic stem cell transplantation (HSCT), both autologous and allogeneic, requires a rapid and durable engraftment, with neutrophil (>500/microL) and platelet (>20,000/microL) reconstitution.
  • Factors influencing engraftment after autologous or allogeneic HSCT were investigated in 65 patients: 25 autologous peripheral stem cell transplantation (PBSCT) and 40 allogeneic bone marrow transplantation (BMT) patients.
  • The type of disease also affected engraftment, where multiple myeloma (MM) and lymphoma showed faster engraftment when compared with leukemia, syndrome myelodysplastic (SMD) and aplastic anemia (AA) and MM presented the best overall survival (OS) in a period of 12 months.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Anemia, Aplastic / mortality. Anemia, Aplastic / therapy. Bone Marrow Transplantation. Female. Humans. Leukemia / mortality. Leukemia / therapy. Lymphoma / mortality. Lymphoma / therapy. Male. Middle Aged. Multiple Myeloma / mortality. Multiple Myeloma / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Peripheral Blood Stem Cell Transplantation. Transplantation, Autologous. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1655-8 [7534140.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3380-9 [11369627.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):698-700 [11553000.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S9-15 [11895159.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):825-32 [12058232.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1620-9 [12393457.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1328-35 [7538556.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2794-800 [8839878.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):600-7 [9103126.001]
  • [Cites] Baillieres Clin Haematol. 1997 Jun;10(2):319-36 [9376667.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Exp Hematol. 1998 May;26(5):409-14 [9590657.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):939-43 [15489866.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Sep;11(9):688-97 [16125639.001]
  • [Cites] Br J Haematol. 2006 May;133(3):305-14 [16643433.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1450-6 [17355954.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70 [18162238.001]
  • [Cites] Pediatr Transplant. 2008 Feb;12(1):14-9 [18086256.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Mar;14(3):301-8 [18275896.001]
  • [Cites] Transfus Apher Sci. 2003 Aug;29(1):53-9 [12877895.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L706-14 [15020295.001]
  • [Cites] N Engl J Med. 1994 Mar 24;330(12):827-38 [8114836.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):750-8 [10984562.001]
  • (PMID = 20357929.001).
  • [ISSN] 1942-0994
  • [Journal-full-title] Oxidative medicine and cellular longevity
  • [ISO-abbreviation] Oxid Med Cell Longev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2763249
  • [Keywords] NOTNLM ; bone marrow transplantation / conditioning regimen / engraftment / hematopoietic stem cell transplantation / peripheral blood stem cell transplantation
  •  go-up   go-down


69. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Koenig KL, Kolonel LN, Laden F, McCullough ML, Parisi D, Purdue MP, Shu XO, Snyder K, Stolzenberg-Solomon RZ, Tworoger SS, Varanasi A, Virtamo J, Wilkens LR, Xiang YB, Yu K, Zeleniuch-Jacquotte A, Zheng W, Abnet CC, Albanes D, Bertrand K, Weinstein SJ: Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol; 2010 Jul 1;172(1):10-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases (total n = 5,491) included incident primary endometrial (n = 830), kidney (n = 775), ovarian (n = 516), pancreatic (n = 952), and upper gastrointestinal tract (n = 1,065) cancers and non-Hodgkin lymphoma (n = 1,353) diagnosed in the participating cohorts.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):21-35 [20562191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1427-37 [16896028.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10213-9 [17047087.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):783-8 [17416771.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):123-8 [17551495.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):236-42 [17696738.001]
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S71-4 [17867373.001]
  • [Cites] Med Sci Sports Exerc. 2007 Oct;39(10):1700-7 [17909395.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Int J Biometeorol. 2000 Nov;44(4):186-9 [11131290.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1867-75 [11920550.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] Cancer. 2002 May 1;94(9):2490-501 [12015775.001]
  • [Cites] Am J Clin Nutr. 2002 Jul;76(1):3-4 [12081814.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):255-65 [15090720.001]
  • [Cites] Clin Chem. 1981 May;27(5):773-4 [7226510.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):373-8 [2839537.001]
  • [Cites] Lancet. 1991 Aug 24;338(8765):464-8 [1678444.001]
  • [Cites] N Engl J Med. 1994 Apr 14;330(15):1029-35 [8127329.001]
  • [Cites] Ann Epidemiol. 1994 Jan;4(1):1-10 [8205268.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):190-7 [7707406.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1133-6 [7721513.001]
  • [Cites] J Clin Epidemiol. 1995 Aug;48(8):1077-85 [7775995.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1297-302 [7658481.001]
  • [Cites] JAMA. 1999 Apr 28;281(16):1505-11 [10227320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):525-32 [10385143.001]
  • [Cites] Health Phys. 2004 Nov;87(5):532-8 [15551791.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):258-61 [15613728.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1123-31 [16236996.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-97-101 [16315387.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):147-54 [16054167.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] Am J Public Health. 2006 Feb;96(2):252-61 [16380576.001]
  • [Cites] Prev Med. 2007 Nov;45(5):327-31 [17395256.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2237-46 [18006912.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S182-94 [18844847.001]
  • [Cites] Am J Clin Nutr. 2008 Dec;88(6):1519-27 [19064511.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Clin Biochem. 2009 Oct;42(15):1549-56 [19631201.001]
  • [Cites] Cancer Causes Control. 2010 Apr;21(4):643-8 [20020320.001]
  • [Cites] Am J Epidemiol. 2006 Jun 1;163(11):1053-64 [16624970.001]
  • (PMID = 20562188.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CP / N02-CP-11010-66; United States / CCR NIH HHS / RC / N01-RC-45035; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / PC / N01-PC35137; United States / NCI NIH HHS / CA / R37 CA70867; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / R37 CA070867; United States / NCI NIH HHS / CA / N01 CN25524; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA49449; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R37 CA54281; United States / CCR NIH HHS / RC / N01-RC-37004; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / CN / N01-CN-45165; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CA / R01 CA82729; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CP / N02CP11010; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522; United States / NCI NIH HHS / CA / K07 CA73790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2892539
  •  go-up   go-down


70. Zarebska-Michaluk DA, Lebensztejn DM, Kryczka WM, Skiba E: Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. Adv Med Sci; 2010;55(1):67-73
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 210 patients with CHC (61.7%) presented at least 1 extrahepatic manifestation, including mixed cryoglobulinemia (37.1%), thrombocytopenia (27.6%), thyroid autoimmunity (16.2%), dermatological disorders (4.1%) and type 2 diabetes (4.1%).
  • Other EM such as the sicca syndrome, nephropathy, polyneuropathy and B-cell lymphoma were observed in single cases.
  • [MeSH-minor] Adolescent. Adult. Aged. Autoimmunity / physiology. Cryoglobulinemia / etiology. Cryoglobulinemia / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Poland. Thrombocytopenia / etiology. Thrombocytopenia / pathology. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371429.001).
  • [ISSN] 1898-4002
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


71. Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA: A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res; 2006 Jul 1;12(13):3993-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
  • PURPOSE: Ultra low doses of interleukin-2 (IL-2) can activate the high-affinity IL-2 receptor constitutively expressed on CD56(bright) natural killer (NK) cells, the CD34+ NK cell precursor, and CD4+ CD25+ regulatory T cells (Tregs) in vivo.
  • We have previously shown synergy between IL-2 and stem cell factor (SCF) in the generation of CD56(bright) NK cells from CD34+ hemopoietic progenitor cells in vitro and showed synergistic NK cell expansion in an in vivo preclinical model.
  • CONCLUSIONS: Administration of IL-2 with SCF is safe and well tolerated and leads to expansion of lymphocyte subsets in patients with HIV or HIV and cancer; however, the changes in NK cell and Treg expansion seen with this cytokine combination were no different than those seen with a similar dose of IL-2 alone.
  • [MeSH-major] Colonic Neoplasms / drug therapy. HIV / drug effects. HIV Infections / drug therapy. Interleukin-2 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Stem Cell Factor / administration & dosage
  • [MeSH-minor] Adult. Antigens, CD56 / immunology. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Humans. Infusions, Intravenous. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Maximum Tolerated Dose. Middle Aged. Remission Induction. T-Lymphocytes, Regulatory / drug effects. T-Lymphocytes, Regulatory / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818697.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA70079; United States / NCI NIH HHS / CA / CA91683; United States / NCI NIH HHS / CA / CA95426
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Interleukin-2; 0 / Stem Cell Factor
  •  go-up   go-down


72. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM: Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant; 2009 May;15(5):547-53
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
  • Diagnoses included diffuse large B-cell lymphoma (n = 18), Burkitt's lymphoma (n = 3), transformed B cell lymphoma (n = 5), mantle cell lymphoma (n = 11), and peripheral T cell lymphoma (n = 9).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Disease Progression. Follow-Up Studies. Graft vs Host Disease. Humans. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7 [18541192.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1893-8 [18949613.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):395-403 [18759762.001]
  • [Cites] Eur J Haematol. 2008 Dec;81(6):425-31 [18774954.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):202-8 [11328303.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):141-8 [11902564.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Cancer. 1979 Aug;44(2):645-51 [383259.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1989 Nov 15;74(7):2579-84 [2804380.001]
  • [Cites] N Engl J Med. 1995 Apr 20;332(16):1045-51 [7898521.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4085-9 [8943841.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):893-9 [9613781.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):645-50 [9818691.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):154-61 [10520036.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):205-13 [15937505.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Blood. 2006 Jul 1;108(1):382-9 [16522821.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • (PMID = 19361746.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA140158
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS561999; NLM/ PMC3953134
  •  go-up   go-down


73. Linet MS, Freedman DM, Mohan AK, Doody MM, Ron E, Mabuchi K, Alexander BH, Sigurdson A, Hauptmann M: Incidence of haematopoietic malignancies in US radiologic technologists. Occup Environ Med; 2005 Dec;62(12):861-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Working as a radiologic technologist was not significantly linked with risk of multiple myeloma (28 cases), non-Hodgkin's lymphoma (118 cases), Hodgkin's lymphoma (31 cases), or chronic lymphocytic leukaemia (23 cases).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Radiol Prot. 2000 Dec;20(4):353-9 [11140709.001]
  • [Cites] Nucleonics. 1949 Dec;5(6):63-6 [15394470.001]
  • [Cites] Health Phys. 2002 Apr;82(4):455-66 [11906134.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):259-67 [12455042.001]
  • [Cites] Semin Ultrasound CT MR. 2002 Oct;23(5):428-42 [12509113.001]
  • [Cites] Am J Epidemiol. 1975 Mar;101(3):199-210 [1115059.001]
  • [Cites] Radiology. 1978 Mar;126(3):677-9 [628739.001]
  • [Cites] Br J Radiol. 1981 Mar;54(639):187-94 [7470779.001]
  • [Cites] JAMA. 1990 Aug 1;264(5):601-4 [2366300.001]
  • [Cites] Br J Radiol. 1991 May;64(761):455-60 [2036572.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):586-98 [1728391.001]
  • [Cites] Radiat Res. 1995 Apr;142(1):1-11 [7899552.001]
  • [Cites] Radiat Res. 1995 May;142(2):117-32 [7724726.001]
  • [Cites] Radiat Res. 1995 Nov;144(2):160-9 [7480642.001]
  • [Cites] Am J Epidemiol. 1997 Jan 1;145(1):72-80 [8982025.001]
  • [Cites] J Radiol Prot. 1999 Mar;19(1):3-26 [10321692.001]
  • [Cites] J Epidemiol. 1999 Apr;9(2):61-72 [10337078.001]
  • [Cites] Radiat Res. 1999 Sep;152(3):280-92 [10453089.001]
  • [Cites] Radiology. 1953 Feb;60(2):186-91 [13112398.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1957 Dec;78(6):988-92 [13478785.001]
  • [Cites] Science. 1963 Dec 13;142(3598):1492-4 [14077037.001]
  • [Cites] Br J Radiol. 2001 Jun;74(882):507-19 [11459730.001]
  • (PMID = 16299095.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-15673; United States / NCI NIH HHS / CP / N01-CP-51016; United States / NCI NIH HHS / CP / N02-CP-81005; United States / NCI NIH HHS / CP / N02-CP-81121
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1740936
  •  go-up   go-down


74. Chadburn A, Hyjek EM, Tam W, Liu Y, Rengifo T, Cesarman E, Knowles DM: Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). Histopathology; 2008 Nov;53(5):513-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Kaposi sarcoma herpesvirus (KSHV) is aetiologically related to Kaposi sarcoma, classical and extracavitary primary effusion lymphoma (PEL; EC-PEL) and multicentric Castleman disease (MCD), entities preferentially occurring in HIV-infected individuals.
  • Characterization of HIV-associated PELs/EC-PELs suggests that the KSHV-infected malignant cells originate from a pre-terminal stage of B-cell differentiation.
  • However, only limited phenotypic studies have been performed on HIV+ MCD, including for PR domain containing 1 with zinc finger domain/B lymphocyte-induced maturation protein 1 (PRDM1/BLIMP1), a key regulator of terminal B-cell differentiation.
  • METHODS AND RESULTS: Double immunohistochemistry and immunohistochemistry-in situ hybridization were used to characterize the KSHV-infected cells in MCD; the results were compared with the phenotypic profiles of 39 PELs/EC-PELs and seven PEL cell lines.
  • [MeSH-major] B-Lymphocytes / virology. Giant Lymph Node Hyperplasia / virology. HIV Infections / complications. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, Primary Effusion / virology
  • [MeSH-minor] Adult. Cell Differentiation. Female. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Male. Middle Aged


75. Li J, Sze DM, Brown RD, Cowley MJ, Kaplan W, Mo SL, Yang S, Aklilu E, Kabani K, Loh YS, Yamagishi T, Chen Y, Ho PJ, Joshua DE: Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood; 2010 Apr 29;115(17):3580-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expansions of CD8(+)CD57(+) T-cell receptor Vbeta-positive (TCRVbeta(+))-restricted cytotoxic T-cell (CTL) clones are found in 48% of patients with multiple myeloma and confer a favorable prognosis.
  • Previous nucleoside analog (NA) therapy, associated with increased incidence of transformation to aggressive lymphoma, significantly influenced the presence of TCRVbeta expansions (chi(2) = 11.6; P < .001), as 83% of patients without (n = 6) and only 7% with (n = 14) TCRVbeta expansions had received NA.
  • By gene set enrichment analysis, CTL clones expressed not only genes from cytotoxic pathways (GZMB, PRF1, FGFBP2) but also genes that suppress apoptosis, inhibit proliferation, arrest cell-cycle G1/S transition, and activate T cells (RAS, CSK, and TOB pathways).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antigens, CD / biosynthesis. Antigens, CD / immunology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / immunology. Humans. Male. Mice. Middle Aged. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Messenger / immunology. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. RNA, Neoplasm / immunology. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / immunology. Receptors, Antigen, T-Cell, alpha-beta / metabolism

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190191.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Neoplasm Proteins; 0 / Nucleosides; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


76. Ellison DA, Parham DM, Sawyer JR: Cytogenetic findings in pediatric T-lymphoblastic lymphomas: one institution's experience and a review of the literature. Pediatr Dev Pathol; 2005 Sep-Oct;8(5):550-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytogenetic analyses of lymphomas commonly reveal nonrandom chromosomal abnormalities, but there are relatively few reports in childhood lymphoblastic lymphoma (LL).
  • Six children (2 to 20 years old) had LL that presented as mediastinal or cervical masses and had a T-cell immunophenotype and clonal abnormalities.
  • Eleven chromosome breakpoints in 6 of our patients (7q11, 12p13, 16p13, 18q21, 9q11, 2p11, 2q13, 7q32, and 7q23) have been reported in other patients with acute lymphoblastic leukemia or LL and involved regions containing TEL, ABL, E2A, MLL, and T-cell receptor-alpha genes.
  • A review of the cytogenetic findings of these and other cases of LL reveals that clonal aberrations are common and most frequently involve T-cell receptor gene regions.
  • [MeSH-major] Chromosome Aberrations. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Karyotyping. Male. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211447.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Haque T, Johannessen I, Dombagoda D, Sengupta C, Burns DM, Bird P, Hale G, Mieli-Vergani G, Crawford DH: A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis; 2006 Sep 1;194(5):584-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purified 72A1 MAb was infused into 1 healthy adult and 4 EBV-seronegative children after liver transplant.
  • No adverse reactions were seen in the adult or in 3 of the transplant recipients.
  • [MeSH-minor] Adult. Animals. Burkitt Lymphoma / immunology. Burkitt Lymphoma / prevention & control. Humans. Mice. Mice, SCID

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897655.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


78. Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol; 2006 Jan;142(1):65-9
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermatomyositis (DM) is a multisystem idiopathic inflammatory disorder that most commonly affects the muscles and skin.
  • OBSERVATIONS: We sought to evaluate the effectiveness of oral mycophenolate mofetil in patients with cutaneous lesions of DM recalcitrant to other therapies through an open-label retrospective medical chart review of patients in a university-affiliated private practice setting.
  • Twelve patients with DM who had skin lesions recalcitrant to traditional therapies or who developed toxic effects from traditional therapies began mycophenolate mofetil treatment at doses ranging from 500 mg to 1 g twice a day.
  • Most patients tolerated mycophenolate mofetil treatment without problem; however, 1 patient developed a B-cell lymphoma of the central nervous system, and another developed abnormal levels of hepatic enzymes along with urinary symptoms.
  • CONCLUSION: Mycophenolate mofetil may be an effective corticosteroid-sparing therapy for the treatment of some patients with DM.
  • [MeSH-minor] Adult. Disease Progression. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Paraneoplastic Syndromes / drug therapy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Dermatomyositis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415388.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 0 / Prodrugs; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


79. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis; 2006 Nov 1;43(9):1198-205
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to describe the laboratory findings and clinical course of MGUS, including association with plasma cell disorders, other malignancies, and infections, in 25 HIV-infected patients with a detectable serum monoclonal protein.
  • Laboratory studies included determination of CD4(+) T lymphocyte cell counts, HIV type 1 loads, and quantitative immunoglobulin levels; serum and urine protein immunoelectrophoresis; and determination of serum viscosity indices.
  • After a mean follow-up duration of 21 months, 7 patients (28%) received a diagnosis of a malignancy (multiple myeloma, in 1 patient; non-Hodgkin lymphoma, in 1; Hodgkin lymphoma, in 1; Kaposi sarcoma, in 2; and plasmacytoma, in 2).
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Lymphoma, AIDS-Related / complications. Male. Middle Aged. Retrospective Studies. Sarcoma, Kaposi / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2006 Nov 1;43(9):1206-8 [17029143.001]
  • (PMID = 17029142.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Ojha J, Islam N, Cohen DM, Marshal D, Reavis MR, Bhattacharyya I: Post-transplant lymphoproliferative disorders of oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 May;105(5):589-96
MedlinePlus Health Information. consumer health - Pancreas Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized histologically by abnormal lymphoid cell proliferation.
  • Although many forms of PTLD do not meet all of the histologic criteria of lymphoma, they often behave clinically in a malignant fashion if left untreated.
  • [MeSH-minor] Adult. Child. DNA, Viral / analysis. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18442744.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunosuppressive Agents
  • [Number-of-references] 33
  •  go-up   go-down


81. Yu JB, Blitzblau RC, Decker RH, Housman DM, Wilson LD: Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol; 2008 Mar 20;26(9):1483-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Primary CD30+ cutaneous lymphoproliferative disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas.
  • [MeSH-major] Antigens, CD30 / analysis. Biomarkers, Tumor / analysis. Lymphoma, T-Cell, Cutaneous / mortality
  • [MeSH-minor] Adolescent. Adult. African Americans / statistics & numerical data. Aged. Aged, 80 and over. Analysis of Variance. Asian Americans / statistics & numerical data. Child. Child, Preschool. European Continental Ancestry Group / statistics & numerical data. Female. Head and Neck Neoplasms / mortality. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. SEER Program. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2008 May 1;26(13):2238
  • (PMID = 18349400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V: Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection; 2008 Jun;36(3):226-30
MedlinePlus Health Information. consumer health - Shingles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Studies showed that diabetes mellitus (DM) is often accompanied by impaired cell-mediated immunity, which potentially may increase the risk for infectious diseases, including herpes zoster (HZ).
  • However, data on the relation between DM and HZ are scarce.
  • This case-control study explored the association between DM and HZ.
  • Personal data on history of DM, lymphoma, leukemia, or AIDS, were obtained from computerized medical records.
  • RESULTS: Adjusted analyses showed that the risk of HZ was associated with history of leukemia, lymphoma, use of steroids or antineoplastic medications, and AIDS, particularly among patients below 45 years of age.
  • In a multivariate analysis, DM was associated with an increased risk of HZ (OR=1.53; 95% CI: 1.44-1.62).
  • CONCLUSIONS: The data suggest that individuals with DM are at increased risk of HZ.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Incidence. Israel / epidemiology. Male. Middle Aged. Population Surveillance. Risk Factors

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454342.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Liang J, Newman JG, Frank DM, Chalian AA: Cervical unicentric Castleman disease presenting as a neck mass: case report and review of the literature. Ear Nose Throat J; 2009 May;88(5):E8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Castleman disease may be mistaken for a malignant process such as lymphoma, it is a benign condition that is curable with complete surgical resection.
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444782.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


84. Toledo RA, Mendonca BB, Fragoso MC, Soares IC, Almeida MQ, Moraes MB, Lourenço DM Jr, Alves VA, Bronstein MD, Toledo SP: Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. Clinics (Sao Paulo); 2010 Apr;65(4):407-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, the mother developed a large virilizing adrenocortical carcinoma and a grade II B-cell non-Hodgkin's lymphoma.
  • No evidence of LOH was observed in the DNA sample from the mother's B-cell lymphoma, and this tumor displayed normal AIP immunostaining.
  • [MeSH-minor] Adolescent. Adult. Female. Gene Expression. Genes, p53. Germ-Line Mutation. Humans. Loss of Heterozygosity / genetics. Multiple Endocrine Neoplasia Type 1 / genetics. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2008 Sep;159(3):259-74 [18524795.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Mar;95(3):1318-27 [20080836.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] Cell Stress Chaperones. 2000 Jul;5(3):243-54 [11005382.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):542-4 [11158006.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Am J Hum Genet. 2002 Dec;71(6):1433-42 [12424709.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5658-61 [12466368.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33351-63 [12810716.001]
  • [Cites] Eur J Endocrinol. 2004 May;150(5):643-8 [15132719.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):216-9 [9920087.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):730-5 [10022445.001]
  • [Cites] Pituitary. 2004;7(2):95-101 [15761658.001]
  • [Cites] Clinics (Sao Paulo). 2006 Feb;61(1):59-70 [16532227.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Feb;50(1):7-16 [16628270.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2558-73 [17167139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4101-5 [17360484.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Apr;66(4):499-502 [17371465.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13656-63 [17329248.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1891-6 [17244780.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1952-5 [17299063.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1934-7 [17341560.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):1-8 [17609395.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Sep;67(3):377-84 [17555499.001]
  • [Cites] Clinics (Sao Paulo). 2007 Aug;62(4):465-76 [17823710.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):750-2 [18272904.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401 [18381572.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Feb;70(2):259-64 [18710468.001]
  • [Cites] Horm Res. 2009 Apr;71 Suppl 2:116-22 [19407507.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • (PMID = 20454499.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  • [Other-IDs] NLM/ PMC2862671
  • [Keywords] NOTNLM ; AIP / Acromegaly / Adrenocortical tumor / FIPA / pituitary tumor
  •  go-up   go-down


85. Head BP, Patel HH, Roth DM, Murray F, Swaney JS, Niesman IR, Farquhar MG, Insel PA: Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. J Biol Chem; 2006 Sep 8;281(36):26391-9
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Depolymerization of microtubules with colchicine (Colch) or actin microfilaments with cytochalasin D (CD) dramatically reduced the amount of caveolin-3 in buoyant (sucrose density) fractions of adult rat cardiac myocytes.
  • Treatment of S49 T-lymphoma cells (which possess lipid rafts but lack caveolae) with CD or Colch redistributed a lipid raft marker (linker for activation of T cells (LAT)) and Galpha(s) from lipid raft domains.
  • [MeSH-minor] Adrenergic beta-Agonists / metabolism. Animals. Caveolins / genetics. Caveolins / metabolism. Cell Fractionation. Cells, Cultured. Colchicine / metabolism. Contractile Proteins / metabolism. Cyclic AMP / metabolism. Cytochalasin D / metabolism. Cytoskeleton / metabolism. Filamins. Isoproterenol / metabolism. Male. Mice. Mice, Knockout. Microfilament Proteins / metabolism. Models, Biological. Myocytes, Cardiac / metabolism. Myocytes, Cardiac / ultrastructure. Nucleic Acid Synthesis Inhibitors / metabolism. Protein Isoforms / genetics. Protein Isoforms / metabolism. Rats. Rats, Sprague-Dawley. Receptors, Adrenergic, beta / metabolism. Receptors, G-Protein-Coupled / metabolism. Sarcolemma / metabolism. Sarcolemma / ultrastructure. Tubulin Modulators / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTOCHALASIN D .
  • Hazardous Substances Data Bank. COLCHICINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818493.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM66232; United States / NHLBI NIH HHS / HL / HL66941
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Adrenergic beta-Agonists; 0 / Caveolins; 0 / Contractile Proteins; 0 / Filamins; 0 / Microfilament Proteins; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Protein Isoforms; 0 / Receptors, Adrenergic, beta; 0 / Receptors, G-Protein-Coupled; 0 / Tubulin Modulators; 22144-77-0 / Cytochalasin D; E0399OZS9N / Cyclic AMP; EC 4.6.1.1 / Adenylyl Cyclases; L628TT009W / Isoproterenol; SML2Y3J35T / Colchicine
  •  go-up   go-down


86. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G: Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol; 2008 Sep-Oct;26(5):887-93
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.
  • RESULTS: Two patients with Jo-1 antibody positive dermatomyositis (DM) demonstrated a clinical response.
  • Re-evaluation of three patients revealed that one had inclusion body myositis, one had sporadic muscular dystrophy and one subsequently developed nodular sclerosing lymphoma.
  • All except one patient showed adequate B cell depletion with re-population occurring 3- >42 months after BCDT.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Muscle Strength. Rituximab

  • Genetic Alliance. consumer health - Idiopathic myopathy.
  • MedlinePlus Health Information. consumer health - Myositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032824.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


87. Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PF, Ngan SY, Powell GJ, Thomas DM: Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer; 2009 Jul 15;125(2):426-31
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A detailed substudy of clinical characteristics was analyzed from 179 AYAs with Hodgkin lymphoma (HL), Ewing sarcoma (ES) or osteosarcomas (OS) treated at a single institution.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19391136.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Ortega MM, Faria RM, Shitara ES, Assis AM, Albuquerque DM, Oliveira JS, Noguti MA, Faria JR, Costa FF, Lima CS: N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma; 2006 Feb;47(2):285-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brazil / epidemiology. Exons. Female. Humans. Male. Middle Aged. Point Mutation. Polymerase Chain Reaction / methods. Prevalence

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321859.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


89. Saggioro D, Silic-Benussi M, Biasiotto R, D'Agostino DM, Ciminale V: Control of cell death pathways by HTLV-1 proteins. Front Biosci (Landmark Ed); 2009;14:3338-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of cell death pathways by HTLV-1 proteins.
  • However, about 3-5% of HTLV-1-infected individuals develop an aggressive T-cell neoplasia (ATLL) or a neurodegenerative disease (TSP/HAM) after a latency period ranging from years to decades.
  • This review summarizes the current knowledge of the effects of the HTLV-1 proteins Tax, p13 and p12 on cell death and survival pathways.
  • Tax, the major oncogenic determinant of HTLV-1, enhances cell survival through its effects on the NF-kappaB, CREB and AKT pathways and on the tumor suppressors p53 and Rb. p13 is targeted to the inner mitochondrial membrane and sensitizes cells to the Fas/ceramide apoptotic pathway and reactive oxygen species-mediated cell death. p12 enhances release of calcium from the endoplasmic reticulum and therefore may influence calcium-dependent apoptotic signals, including opening of the mitochondrial permeability transition pore.
  • The long-term fate of HTLV-1-infected cells (apoptosis, survival, transformation) may therefore depend on the balance of the effects of Tax, p13 and p12 on cell death pathways.
  • [MeSH-major] Cell Death / physiology. Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Viral Proteins / physiology
  • [MeSH-minor] Cell Proliferation. Cell Survival. Homeostasis. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273278.001).
  • [ISSN] 1093-4715
  • [Journal-full-title] Frontiers in bioscience (Landmark edition)
  • [ISO-abbreviation] Front Biosci (Landmark Ed)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Number-of-references] 137
  •  go-up   go-down


90. Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, Treon SP: CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma; 2005 Mar;5(4):246-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD5, CD10, and CD23 are cell surface antigens used to distinguish B-cell disorders.
  • The expression of these antigens and their clinical significance in Waldenstrom's macroglobulinemia (WM), an uncommon B-cell disorder, remains to be clarified.
  • Importantly, we also correlated laboratory and clinical data, as well as existence of a familial history of a B-cell disorder in view of reports suggesting familial predisposition in WM.
  • These studies demonstrated tumor cell expression of CD5, CD10, and CD23 in 15 of 171 patients (9%), 11 of 161 patients (7%), and 37 of 105 patients (35%), respectively.
  • No differences in age at diagnosis; presence of adenopathy and/or splenomegaly; bone marrow involvement; serum IgA, IgB, and b2 macroglobulin levels; hematocrit; platelet count; or familial history of WM or a related B-cell disorder were observed among patients with and without CD5, CD10, and CD23 expression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Flow Cytometry. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794857.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA 087977-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Receptors, IgE; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


91. Davidović LB, Sindjelić RB, Savić NB, Kostić DM, Svetković SD, Kuzmanović IB, Marković DM, Marković MM, Cinara IS, Maksimović ZL: [Surgical treatment of abdominal tumours closely related to major blood vessels]. Srp Arh Celok Lek; 2008 May-Jun;136(5-6):241-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the most frequent were the following: renal carcinoma in 14 patients, teratoma in 7, liposarcoma in 5, fibrosarcoma and lymphoma in 3 patients.
  • Intraoperative blood cell saving and autotransfusion were applied in 27 patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Vessel Prosthesis Implantation. Child. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18792619.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


92. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H: Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol; 2008 Jul;9(7):683-92
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The top five cancers in males--Kaposi's sarcoma (constituting 12.9% of all cancers in males) and cancer of the liver (14.8%), prostate (9.5%), bladder (6.1%), and non-Hodgkin lymphoma (5.7%)--and in females--cancer of the cervix (constituting 23.3% of all cancers in females) and breast (19.2%), Kaposi's sarcoma (5.1%), cancer of the liver (5.0%), and non-Hodgkin lymphoma (3.7%)--are discussed in detail.
  • [MeSH-minor] Adolescent. Adult. Africa / epidemiology. Age Distribution. Child. Child, Preschool. Cost of Illness. Female. Humans. Incidence. Infant. Male. Middle Aged. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18598933.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


93. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM: Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2010 Jan 5;107(1):252-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
  • The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets.
  • We demonstrate that CRLF2 is overexpressed in approximately 15% of adult and high-risk pediatric B-ALL that lack MLL, TCF3, TEL, and BCR/ABL rearrangements, but not in B-ALL with these rearrangements or other lymphoid malignancies.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cytokine / genetics. Signal Transduction / physiology
  • [MeSH-minor] Adult. Child. Cytokines / metabolism. DNA Mutational Analysis. Female. Humans. Janus Kinase 2 / genetics. Janus Kinase 2 / metabolism. Male. Mutation. Prognosis. Survival Rate. Transcription, Genetic


94. Madson DM, Opriessnig T: Multicentric T-cell lymphosarcoma in a white-tailed deer (Odocoileus virginianus). J Wildl Dis; 2009 Jul;45(3):791-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric T-cell lymphosarcoma in a white-tailed deer (Odocoileus virginianus).
  • An adult female white-tailed deer (Odocoileus virginianus) with a history of shaking, ataxia, and severe debilitation was submitted for examination.
  • Similar lymphoblasts were associated with the leptomeninges, choroid plexus, and the intestinal mucosa; these cells were intensely positive for CD3 antigen, indicating their T-cell origin.
  • [MeSH-major] Deer. Lymphoma, T-Cell / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617490.001).
  • [ISSN] 0090-3558
  • [Journal-full-title] Journal of wildlife diseases
  • [ISO-abbreviation] J. Wildl. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Seidler AM, Gottlieb AB: Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol; 2008 Nov;59(5):872-80
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Drugs have occasionally been implicated in dermatomyositis (DM) onset.
  • OBJECTIVE: We sought to review case reports of drug-induced DM.
  • Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis).
  • Of the sample, 84.3% had improvement of DM after discontinuation of the drug.
  • [MeSH-minor] Adult. Aged. Antibodies, Antinuclear / analysis. Autoimmune Diseases / drug therapy. Cyclophosphamide / adverse effects. Etoposide / adverse effects. Female. Humans. Hydroxyurea / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625537.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 27
  •  go-up   go-down


96. Heresi GA, Wang J, Taichman R, Chirinos JA, Regalado JJ, Lichtstein DM, Rosenblatt JD: Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol; 2005 Jul-Aug;23(4):261-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We performed a MEDLINE (National Library of Medicine, Bethesda, MD) database search for case reports during the last 32 years using "prostate cancer," "lymphadenopathy," "metastatic to lymph nodes," and "mimicking lymphoma" as keywords.
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Receptors, CCR7

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018941.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / Receptors, CCR7; 0 / Receptors, Chemokine
  • [Number-of-references] 39
  •  go-up   go-down


97. Gollub MJ, Hong R, Sarasohn DM, Akhurst T: Limitations of CT during PET/CT. J Nucl Med; 2007 Oct;48(10):1583-91
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 100 patients, the most common malignancies were lymphoma (n = 37), cancer of the colorectum (n = 31), and esophageal cancer (n = 15).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Humans. Middle Aged. Observer Variation. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873133.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Ruggero K, Corradin A, Zanovello P, Amadori A, Bronte V, Ciminale V, D'Agostino DM: Role of microRNAs in HTLV-1 infection and transformation. Mol Aspects Med; 2010 Oct;31(5):367-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus that infects more than 20 million people worldwide, is the etiological agent of ATLL (adult T-cell leukemia/lymphoma), an aggressive leukemia of CD4+ T lymphocytes which arises in a small percentage of infected individuals after a long clinical latency.
  • Tumor emergence is attributed primarily to the oncogenic activity of the viral protein Tax, which drives the expression of viral transcripts and controls the expression and function of a broad variety of host-cell genes involved in proliferation, genetic stability and apoptosis.
  • In the present review we discuss recent data demonstrating changes in cellular microRNA expression in HTLV-1-infected cell lines and ATLL cells, and the functional impact of a subset microRNAs deregulated by HTLV-1 on cellular gene expression and signal transduction pathways.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. HTLV-I Infections / genetics. Human T-lymphotropic virus 1 / pathogenicity. Human T-lymphotropic virus 1 / physiology. MicroRNAs / metabolism
  • [MeSH-minor] Gene Expression Regulation, Leukemic / genetics. Humans. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20600265.001).
  • [ISSN] 1872-9452
  • [Journal-full-title] Molecular aspects of medicine
  • [ISO-abbreviation] Mol. Aspects Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


99. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M: Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis; 2009 Apr 15;48(8):1138-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy.
  • The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70-14.92).
  • Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (non-Hodgkin's lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55-9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76-3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08-2.00]).

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 13;360(9327):119-29 [12126821.001]
  • [Cites] JAMA. 2003 May 21;289(19):2554-9 [12759327.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):180-9 [15249567.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1425-31 [6272109.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] JAMA. 1987 Sep 4;258(9):1143-5, 1149, 1153-4 [3041060.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):184-9 [1676252.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(10):1059-71 [1890600.001]
  • [Cites] JAMA. 1992 Nov 18;268(19):2662-6 [1359163.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] BMJ. 1994 Apr 23;308(6936):1068-73 [7909698.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2107-25 [7846414.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Arch Intern Med. 1995 Jul 24;155(14):1537-42 [7605156.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] AIDS. 1998 Jan 1;12(1):29-33 [9456252.001]
  • [Cites] Nat Med. 1998 Feb;4(2):208-14 [9461195.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] Infection. 2005 Feb;33(1):43-5 [15750761.001]
  • [Cites] BMJ. 2005 Mar 12;330(7491):594-6 [15761002.001]
  • [Cites] J Infect Dis. 2005 Sep 15;192(6):992-1002 [16107951.001]
  • [Cites] Lancet. 2006 Mar 11;367(9513):817-24 [16530575.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] AIDS. 2007 May 31;21(9):1185-97 [17502729.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1867-75 [17721094.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8 [11141245.001]
  • [Cites] J Infect Dis. 2002 Jan 15;185(2):178-87 [11807691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95 [11917244.001]
  • (PMID = 19275498.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA013566-08; United States / NIAAA NIH HHS / AA / U10 AA013566; United Kingdom / Medical Research Council / / G0700820; United States / NIAAA NIH HHS / AA / U10 AA013566-08
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS264818; NLM/ PMC3032444
  • [Investigator] Casabona J; Chêne G; Costagliola D; Dabis F; D'Arminio Monforte A; de Wolf F; Egger M; Fatkenheuer G; Gill J; Hogg R; Justice A; Kitahata M; Ledergerber B; Mocroft A; Phillips A; Reiss P; Saag M; Sabin C; Staszewski S; Weller I; May M; Harris R; Sterne J; Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Guiguet M; Kousignian I; Lanoy E; Lièvre L; Potard V; Selinger-Leneman H; Bouvet E; Crickx B; Ecobichon JL; Leport C; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Roudière L; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit P; Desplanque N; Meyohas MC; Picard O; Cadranel J; Mayaud C; Bricaire F; Herson S; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Trepo C; Ravaux I; Delmont JP; Moreau J; Gastaut JA; Retornaz F; Soubeyrand J; Allegre T; Blanc PA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; May T; Rabaud C; Raffi F; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Yasdanpanah Y; Pradinaud R; Sobesky M; Contant M; Montroni M; Scalise G; Braschi MC; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Arici C; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Cosco L; Scerbo A; Vecchiet J; D'Alessandro M; Santoro D; Pusterla L; Carnevale G; Lorenzotti S; Viganò P; Mena M; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Grima P; Grima PF; Pagano G; Cassola G; Alessandrini A; Piscopo R; Toti M; Trezzi M; Soscia F; Tacconi L; Orani A; Perini P; Scasso A; Vincenti A; Chiodera F; Castelli P; Scalzini A; Palvarini L; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Cicconi P; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Abrescia N; Chirianni A; Izzo CM; Piazza M; De Marco M; Viglietti R; Manzillo E; Nappa S; Colomba A; Abbadessa V; Prestileo T; Mancuso S; Ferrari C; Pizzaferri P; Filice G; Minoli L; Bruno R; Novati S; Baldelli F; Camanni G; Petrelli E; Cioppi A; Alberici F; Ruggieri A; Menichetti F; Martinelli C; De Stefano C; La Gala A; Ballardini G; Rizzo E; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Dianzani F; Ippolito G; Antinori A; Antonucci G; Ciardi M; Narciso P; Petrosillo N; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Noto P; Lichtner M; Capobianchi MR; Carletti F; Girardi E; Pezzotti P; Rezza G; Mura MS; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Grossi PA; Basilico C; Poggio A; Bottari G; Raise E; Ebo F; Pellizzer G; Buonfrate D; Resta F; Loso K; Cozzi Lepri A; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Gorgievski M; Günthard H; Hirsch H; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Martinetti G; Martinez B; Müller N; Nadal D; Opravil M; Paccaud F; Pantaleo G; Rickenbach M; Rudin C; Schmid P; Schultze D; Schüpbach J; Speck R; Taffé P; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S; Gras LA; van Sighem AI; Smit C; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Branger J; Eeftinck Schattenkerk JK; Gisolf J; Godfried MH; Lange JM; Lettinga KD; van der Meer JT; Nellen FJ; van der Poll T; Ruys TA; Steingrover R; Vermeulen JN; Vrouenraets SM; van Vugt M; Wit FW; Kuijpers TW; Pajkrt D; Scherpbier HJ; van Eeden A; Brinkman K; van den Berk GE; Blok WL; Frissen PH; Roos JC; Schouten WE; Mulder JW; van Gorp EC; Wagenaar J; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen MG; Richter C; van der Berg J; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Pogány K; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; van Assen S; van Leeuwen JT; Doedens R; Scholvinck EH; ten Kate RW; Soetekouw R; van Houte D; Polée MB; Kroon FP; van den Broek PJ; van Dissel JT; Schippers EF; Schreij G; van der Geest S; Lowe S; Verbon A; Koopmans PP; Van Crevel R; de Groot R; Keuter M; Post F; van der Ven AJ; Warris A; van der Ende ME; Gyssens IC; van der Feltz M; Nouwen JL; Rijnders BJ; de Vries TE; Driessen G; van der Flier M; Hartwig NG; Juttman JR; van Kasteren ME; Van de Heul C; Hoepelman IM; Schneider MM; Bonten MJ; Borleffs JC; Ellerbroek PM; Jaspers CA; Mudrikove T; Schurink CA; Gisolf EH; Geelen SP; Wolfs TF; Faber T; Tanis AA; Groeneveld PH; den Hollander JG; Duits AJ; Winkel K; Back NK; Bakker ME; Berkhout B; Jurriaans S; Zaaijer HL; Cuijpers T; Rietra PJ; Roozendaal KJ; Pauw W; van Zanten AP; Smits PH; von Blomberg BM; Savelkoul P; Pettersson A; Swanink CM; Franck PF; Lampe AS; Jansen CL; Hendriks R; Benne CA; Veenendaal D; Storm H; Weel J; van Zeijl JH; Kroes AC; Claas HC; Bruggeman CA; Goossens VJ; Galama JM; Melchers WJ; Poort YA; Doornum GJ; Niesters MG; Osterhaus AD; Schutten M; Buiting AG; Swaans CA; Boucher CA; Schuurman R; Boel E; Jansz AF; Veldkamp A; Beijnen JH; Huitema AD; Burger DM; Hugen PW; van Kan HJ; Losso M; Duran A; Vetter N; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Poll B; Colebunders R; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Lundgren J; Benfield T; Kirk O; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Oestergaard L; Zilmer K; Ristola M; Girard PM; Vanhems P; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Bogner J; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambattakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Maayan S; Chiesi A; Mazeu I; Pristera R; Gabbuti A; Montesarchio E; Gargiulo M; Iacomi F; Vlassi C; Finazzi R; Galli M; Ridolfo A; Rozentale B; Aldins P; Chaplinskas S; Hemmer R; Staub T; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Soriano V; Martin-Carbonero L; Labarga P; Clotet B; Jou A; Conejero J; Tural C; Gatell JM; Miró JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Persson PO; Flamholc L; Boffi E; Kravchenko E; Chentsova N; Barton S; Johnson AM; Mercey D; Johnson MA; Murphy M; Weber J; Scullard G; Fisher M; Brettle R; Gatell J; Gazzard B; Friis-Møller N; Bannister W; Ellefson M; Borch A; Podlekareva D; Holkmann Olsen C; Kjaer J; Peters L; Reekie J; Raffanti S; Dieterch D; Becker S; Scarsella A; Fusco G; Most B; Balu R; Rana R; Beckerman R; Ising T; Fusco J; Irek R; Johnson B; Hirani A; DeJesus E; Pierone G; Lackey P; Irek C; Johnson A; Burdick J; Leon S; Arch J; Helm EB; Carlebach A; Müller A; Haberl A; Nisius G; Lennemann T; Stephan C; Bickel M; Mösch M; Gute P; Locher L; Lutz T; Klauke S; Knecht G; Khaykin P; Doerr HW; Stürmer M; Babacan E; von Hentig N; Beylot J; Dupon M; Longy-Boursier M; Pellegrin JL; Ragnaud JM; Salamon R; Thiébaut R; Lewden C; Lawson-Ayayi S; Dupon M; Mercié P; Moreau JF; Morlat P; Bernard N; Lacoste D; Malvy D; Neau D; Blaizeau MJ; Decoin M; Delveaux S; Hannapier C; Labarrère S; Lavignolle-Aurillac V; Uwamaliya-Nziyumvira B; Palmer G; Touchard D; Balestre E; Alioum A; Jacqmin-Gadda H; Bonarek M; Bonnet F; Coadou B; Gellie P; Nouts C; Bocquentin F; Dutronc H; Lafarie S; Aslan A; Pistonne T; Thibaut P; Vatan R; Chambon D; De La Taille C; Cazorla C; Ocho A; Viallard JF; Caubet O; Cipriano C; Lazaro E; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Breilh D; Blanco P; Loste P; Caunègre L; Bonnal F; Farbos S; Ferrand M; Ceccaldi J; Tchamgoué S; De Witte S; Buy E; Alexander C; Barrios R; Braitstein P; Brumme Z; Chan K; Cote H; Gataric N; Geller J; Guillemi S; Harrigan PR; Harris M; Joy R; Levy A; Montaner J; Montessori V; Palepu A; Phillips E; Phillips P; Press N; Tyndall M; Wood E; Yip B; Bhagani S; Breen R; Byrne P; Carroll A; Cuthbertson Z; Dunleavy A; Geretti AM; Heelan B; Johnson M; Kinloch-de Loes S; Lipman M; Madge S; Marshall N; Nair D; Nebbia G; Prinz B; Shah S; Swader L; Tyrer M; Youle M; Chaloner C; Grabowska H; Holloway J; Puradiredja J; Ransom D; Tsintas R; Bansi L; Fox Z; Harris E; Hill T; Lampe F; Lodwick R; Smith C; Amoah E; Booth C; Clewley G; Garcia Diaz A; Gregory B; Janossy G; Labbett W; Thomas M; Read R; Krentz H; Beckthold B; Schmeisser N; Alquézar A; Esteve A; Podzamczer D; Murillas J; Romero A; Agustí C; Agüero F; Ferrer E; Riera M; Segura F; Navarro G; Force L; Vilaró J; Masabeu A; García I; Guadarrama M; Montoliu A; Ortega N; Lazzari E; Puchol E; Sanchez M; Blanco JL; Garcia-Alcaide F; Martinez E; Mallolas J; López-Dieguez M; García-Goez JF; Sirera G; Romeu J; Negredo E; Miranda C; Capitan MC; Olmo M; Barragan P; Saumoy M; Bolao F; Cabellos C; Peña C; Sala M; Cervantes M; Jose Amengual M; Navarro M; Penelo E; Barrufet P; Raper JL; Mugavero MJ; Willig JH; Schumacher J; Chang PW; Westfall AO; Cloud G; Lin HY; Acosta EP; Colette-Kempf M; Allison JJ; Pisu M
  •  go-up   go-down


100. Lowenthal RM, Tuck DM, Bray IC: Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative disorders: a case-control study. Intern Med J; 2007 Sep;37(9):614-9
MedlinePlus Health Information. consumer health - Electromagnetic Fields.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Case-control study of 854 patients diagnosed with LPD or MPD (including leukaemia, lymphoma and related conditions) aged 0-94 years comprising all cases diagnosed in Tasmania between 1972 and 1980.
  • RESULTS: Compared with those who had always lived >300 m from a power line, those who had ever lived within 50 m had an odds ratio (OR) of 2.06 (95% confidence interval 0.87-4.91) for developing LPD or MPD (based on 768 adult case-control pairs); those who had lived between 50 and 300 m had an OR of 1.30 (0.88-1.91).
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Risk Factors. Tasmania / epidemiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med J. 2008 Sep;38(9):746; author reply 746-7 [19143897.001]
  • [CommentIn] Intern Med J. 2007 Dec;37(12):841 [18028096.001]
  • (PMID = 17543004.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down






Advertisement